## ORIGINAL ARTICLE

Check for updates

Tavlor & Francis

Taylor & Francis Group

# Association between diabetes and dental implant complications: a systematic review and meta-analysis

## Xue Jiang<sup>a</sup>, Yanlin Zhu<sup>b</sup>, Zhaoying Liu<sup>a</sup>, Zilu Tian<sup>a</sup> and Song Zhu<sup>a,c</sup> D

<sup>a</sup>Department of Prosthodontics, School and Hospital of Stomatology, Jilin University, Changchun, Jilin, P.R. China; <sup>b</sup>Department of Dental Implantology, School and Hospital of Stomatology, Jilin University, Changchun, Jilin, P.R. China; <sup>c</sup>Department of Prosthodontics, Hospital of stomatology, Jilin University, Changchun, Jilin, P.R. China

#### ABSTRACT

**Objectives:** The aim of this study was to explore the possible association between diabetes mellitus and dental implant complications.

**Material and methods:** A systematic literature review was conducted to answer the following PICO (Participants, Intervention, Comparison, and Outcome) question: Is there association between diabetes mellitus and dental implant complications? Two independent searchers performed a literature search of the PubMed/MEDLINE, Web of Science, Cochrane Library and EMBASE databases for studies published until February 2020, focussing on studies including continuous outcomes, marginal bone loss (primary outcome), probing depth, and bleeding upon probing (secondary outcomes).

**Results and conclusions**: A final total of 10 published studies were included in this systematic review. There were statistically significant differences between the groups with regard to marginal bone loss (p < .00001), probing depth (p < .00001) and bleeding around dental implants (p < .00001), and subjects without diabetes had lower complication rates. Additionally, in the subgroup analysis performed with loading time and HbA1c levels, a more evident association was found in immediate loading for probing depth. Moreover, the analysis results of bleeding around dental implants suggested that as HbA1c level increases, the bleeding of the tissues surrounding the implant will also increase. With regard to dental implant complications, there were statistically significant differences favouring patients without diabetes mellitus.

## Introduction

Diabetes mellitus comprises a group of metabolic disorders that are characterized by hyperglycaemia, which is caused by defective insulin secretion, dysfunction or both. According to the latest statistics from the International Diabetes Federation, the number of people aged 20 to 79 years with diabetes mellitus had risen to 424.9 million in 2017, roughly three times the prevalence in 2000. The number of patients with diabetes worldwide is expected to rise to 629 million by 2045[1]. Diabetes mellitus is closely related to oral health, especially periodontal health [2], and has long been known to be a risk factor for implant failure due to susceptibility to infection, impaired healing and other complications [3]. Although diabetes mellitus has always been considered a relative contraindication to treatment with dental implants [4], dental implant restoration has been increasingly favoured by the majority of patients with tooth loss due to its advantages of reduced damage to adjacent teeth and reduced impact on alveolar bone compared to fixed bridge treatment and removable restoration, respectively [5]. A recent study surveyed a 40-year trend of tooth loss among people over the age of 25 years with and without diabetes mellitus in the United States and found that patients with diabetes lost almost twice as many teeth as patients without diabetes [6]. This observation corresponds to an increasing need for den-

tal implant restoration among patients with diabetes.

Long-term hyperglycaemia may injure the vascular endothelium, leading to pathological changes of large vessels or microvessels, which promotes the differentiation of osteoclasts and inhibits the proliferation and differentiation of osteoblasts [7]. Hyperglycaemia also leads to excessive immune response to pathogens. Inflammatory mediators closely related to diabetes, such as interleukin-1 $\beta$  (IL-1 $\beta$ ), interleukin-6 (IL-6), interleukin-8 (IL-8) and tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ), can all be detected in the gingiva, serum and saliva. The presence of these factors aggravates the inflammation of oral tissues and reduces collagen synthesis, thereby effecting the formation of bone matrix and effecting the healing of both hard and soft tissues [8].

Although implants have a relatively high success rate during routine procedures, dentists need to identify patients at higher risk of complications, such as peri-implantitis and peri-implant mucositis. However, for many years, the definition of peri-implant diseases has been controversial. Although these diseases were initially classified as periodontal diseases, the specificity of peri-implant bone remodelling,

CONTACT Song Zhu 😨 zhusong1965@163.com 😰 Department of Prosthodontics, Hospital of Stomatology, Jilin University, 1500 Qinghua Road, Chaoyang District, Changchun, Jilin, 130012, P.R. China © 2020 Acta Odontologica Scandinavica Society

#### **ARTICLE HISTORY**

Received 28 December 2019 Revised 17 March 2020 Accepted 20 April 2020

#### **KEYWORDS**

Dental implants; diabetes mellitus; meta-analysis the loss of periodontal ligaments, and other factors complicate the diagnosis of peri-implant diseases [9,10]. Recently, marginal bone loss (MBL), probing depth (PD) and bleeding on probing (BOP) have been used to identify peri-implant diseases. MBL is considered to be an important factor in evaluating the quality of survival bone, as bone loss may lead to the formation of pockets [11]. PD and BOP are indispensable parameters of peri-implant inflammation. Changes in the three indicators listed above may ultimately lead to adverse implant outcomes [12]. Considering the high prevalence of diabetes mellitus and the increasing number of people who expect to use dental implants to restore missing teeth, the aim of this meta-analysis was to conduct a review of the literature to explore a possible association between diabetes mellitus and dental implant complications. The null hypotheses were as follows: 1) There is no difference between individuals with and without diabetes mellitus in terms of peri-implant marginal bone loss. 2) There are no differences between these groups regarding indicators of probing depth and bleeding on probing.

## **Methods**

#### Protocol and registration

This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [13] and was registered with PROSPERO, the international prospective register of systematic reviews (PROSPERO: CRD42019143213).

#### **Eligibility criteria**

The PICO that we used to guide article selection was as follows. Population: individuals with dental implants; intervention: patients with diabetes mellitus; comparison: healthy patients without any sign of diabetes mellitus; and outcomes: complications containing MBL (primary outcome), PD and BOP (secondary outcomes). The focussed question to be addressed was: Is there association between diabetes mellitus and dental implant complications?

The following inclusion criteria were adopted: 1) studies of both diabetes (study) patients and healthy (control) participants; 2) randomized controlled trials (RCTs) and retrospective or prospective cohort studies; 3) available MBL, PD and BOP values; 4) study duration  $\geq$ 6 months; 5) sample size of each group  $\geq$ 10 participants; and 6) no language restrictions. The exclusion criteria were: 1) reviews or case reports and 2) animal studies.

## Search strategy

Both electronic and manual searches were performed of electronic the PubMed/MEDLINE, Web of Science, Cochrane Library, EMBASE databases, system for information on Grey literature in Europe (http://www.opengrey.eu) and the ClinicalTrials.gov database (www.clinicaltrials.gov). The databases were searched for relevant literature published until February 2020. In addition, manual search was performed in the following journals for studies published between June 2016 and February 2020: Journal of Periodontology, Journal of Dental Research, Journal of Periodontal Research, Clinical Oral Implants Research, and Clinical Implant Dentistry and Related Research. References related to the included articles were also screened to determine whether they met the inclusion criteria. We used combinations of medical subject heading (MeSH) terms and free text words for all searches. To avoid missing any relevant literature, we combined population (Dental Implants[MeSH] OR dental implants[All Fields] (surgical[All Fields] AND dental[All Fields] AND OR prosthesis[All Fields]) with intervention (Diabetes Mellitus[MeSH] OR Diabetes Insipidus [MeSH] OR Diabetes Complications[MeSH] OR Diabetes Mellitus[MeSH] OR Type 2, Diabetes Mellitus, Type 1). The search strategy framework is shown in Table 1.

#### Data collection and extraction

According to the inclusion and extraction criteria, two reviewers independently screened the titles and abstracts and read the full text of papers for which final inclusion was difficult to decide. We extracted the following data: first author name, title, study design, country, sex ratio, average age, HbA1c, MBL, PD, and BOP. If the experiment had multiple follow-ups, we selected the data from the last followup. If the important data were not available in the paper, we contacted the corresponding author by email to request the missing data; if no response was received after a reminder, the study was excluded from the review.

## Risk of bias and quality assessment

The retrospective and prospective cohort studies that we included in our review were assessed by the Newcastle-Ottawa scale (NOS)[14], in which a maximum of one star was scored for the selection and outcome categories, and two stars were scored for compatibility. A study can earn up to nine stars. If the score is equal to or more than 7, the research quality is considered high. If the score is between 4 and 6, the study is considered to be moderate quality.

## Statistical analysis

Review Manager 5.3 software was used for the analysis of the data and to construct the forest plots. The three outcomes extracted in this review were all continuous variables, for which the mean and standard deviation (SD) were used to calculate the mean difference (MD) in millimetres with a 95% CI. When only standard error of mean (SEM) was mentioned, the SD could be obtained by indirect calculation. The heterogeneity of the results was tested by the Q method, and the  $I^2$  statistic was used to express the percentage of variation attributable to heterogeneity. When there was no statistically significant heterogeneity (p > .1,  $I^2 < 50\%$ ) between studies, we conducted the analysis using a fixed effects model. However,

Database	Search strategy
PUBMED	(((("Diabetes Mellitus"[Mesh] OR "Diabetes Insipidus"[Mesh]) OR "Diabetes Complications"[Mesh]) OR "Diabetes Mellitus, Type 2"[Mesh]) OR "Diabetes Mellitus, Type 1"[Mesh]) AND ((((((("Dental Implants"[Mesh] OR ("dental implants"[MeSH Terms] OR ("dental"[All Fields] AND "implants"[All Fields]) OR "dental implants"[All Fields] OR ("implants"[All Fields] AND "dental"[All Fields]) OR "dental implants"[All Fields] OR ("dental"[All Fields]) OR "dental implants"[All Fields] OR ("dental"[All Fields]) OR "dental implants"[All Fields] OR ("dental"[All Fields])) OR ("dental implants"[All Fields] OR ("dental"[All Fields])) OR ("dental implants"[All Fields] AND "surgical"[All Fields])) OR ("dental implants"[MeSH Terms] OR ("dental"[All Fields] AND "implants"[All Fields] OR "dental implants"[All Fields] OR ("surgical"[All Fields] AND "dental"[All Fields] AND "dental"[All Fields] AND "mosthesis"[All Fields]) OR "dental implants"[All Fields] OR ("dental"[All Fields] AND "dental"[All Fields] AND "surgical dental prosthesis"[All Fields] OR ("dental implants"[MeSH Terms] OR ("dental"[All Fields]) OR "dental implants"[All Fields] AND "implants"[All Fields] OR "dental implants"[All Fields] AND "implants"[All Fields]) OR "dental implants"[All Fields] AND "implants"[All Fields] OR "dental implants"[All Fields] OR ("dental"[All Fields]) OR "dental implants"[All Fields] OR ("dental"[All Fields]) OR "dental implants"[All Fields] OR ("dental"[All Fields])) OR ("dental implants"[All Fields] OR ("dental"[All Fields])) OR ("dental implants"[All Fields]) OR "dental implants"[All Fields] OR ("dental"[All Fields])) OR "dental implants"[All Fields])) OR ("dental implants"[All Fields]) OR "dental implants"[All Fields]) OR "dental implants"[All Fields])) OR ("dental implants"[All Fields]) OR "dental implants"[All Fields]) OR "dental implants"[All Fields])) OR ("dental implants"[All Fields])) OR ("denta
Web of Science	#1 diabetes #2 dental implant #1 and #2
Cochrane Library	<ul> <li>#1 ("diabetes insipidus"):ti,ab,kw OR ("diabetes mellitus"):ti,ab,kw OR ("diabetes mellitus type 1"):ti,ab,kw OR ("diabetes mellitus type 2"):ti,ab,kw OR (diabetes complications):ti,ab,kw</li> <li>#2 (dental implant):ti,ab,kw</li> <li>#3 - #1 AND #2</li> </ul>
Embase	<ul> <li>#1 'tooth implantation' OR 'tooth implant' OR 'dental abutment' OR 'single tooth implant' OR 'dental anchor' OR (dental AND implant AND complication)</li> <li>#2 'diabetes mellitus' OR 'non insulin dependent diabetes mellitus' OR 'diabetic complication'</li> <li>#3-#1 AND #2</li> </ul>

if the heterogeneity was statistically significant (p < .1,  $l^2 > 50\%$ ), a random effects model was adopted [15,16].

Subgroup analysis was used to explore whether some factors (HbA1c, loading time, follow-up time) were the source of heterogeneity. Publication bias was identified by Egger's regression test using STATA 14 statistical software and funnel plots [17].

## Results

## Literature search

Table 1 Search strategy

The process for searching and selecting articles is shown in Figure 1. According to the set search strategy, a total of 1153 articles were initially retrieved: 215 articles from PubMed/ MEDLINE, 558 from Web of Science, 31 from Cochrane Library, and 349 from EMBASE. After eliminating 461 duplicates, 692 articles remained. Following the screening of titles and abstracts, 525 studies were determined to be irrelevant to our subject, 48 described animal experiments, 42 were reviews, and 7 were case reports. Among the 70 remaining articles, 50 were excluded after full-text analysis. Of the remaining 20 studies [18-37], 10 were excluded for the following reasons [22,23,30-37]. 1) The implants in one study had been functioning for approximately 6.5 years at the time of the study, but disease duration in the diabetes and prediabetes groups was 2 or 3 years; in other words, some patients did not have diabetes at the time of implantation, which may make the final results unreliable [23]. 2) The mean values of MBL, DB and BOP provided in some of the papers did not meet the data extraction standards of this meta-analysis, and relevant data were not obtained after contacting the corresponding authors [30,31,33,35]. 3) After comparison, it was determined that two studies by Al Amri MD [24,32], Al Zahrani S [21,34] and Cabrera-Domínguez [19,22] may have been from the same team, and there may have been data overlap between the papers. The articles by Al Amri [32] and Cabrera-Domínguez [22] had minimal content and a short observation time and were excluded. We also excluded the study by Al Zahrani S because the control group was well-controlled patients with diabetes rather than healthy individuals [34]. 4) Finally, selected patients had pairs of adjacent implants, which may influence MBL, PD and BOP [36,37].

## **Characteristics of included studies**

The characteristics of the included studies in this review are shown in Table 2. Eight were prospective cohort studies [18,21,24-29], and two were retrospective cohort studies [19,20]. Of the 625 participants in all of the studies, 360 had diabetes, and 265 were healthy. The number of participants ranged from 24 to 119, with an average age ranging from 43.1 to 65 years. Three studies were grouped according to HbA1c levels [24,25,27]. Two of the studies [24,25] divided the diabetes group into groups with HbA1c levels of 6.1-8.0% (well-controlled) and 8.1-10.0% (moderately controlled), while the other [27] added a group with HbA1c levels of  $\geq$ 10.0% (poorly controlled). Two of the studies [24,25] recruited participants with immediately loaded implants, while the patients in six studies [18,19,21,26,27,29] received implants with delayed loading; the remaining two studies did not describe loading [20,28].

#### Quality assessment

The quality analysis results of the studies are shown in Table 3. The mean NOS score of the 10 studies was  $6.3 \pm 1.3$ .



Figure 1. PRISMA flow diagram of the study selection process.

#### Results of the meta-analysis

This review evaluated three outcome indicators: MBL, PD, and BOP. Among these studies, nine compared MBL [18,19,21,24–29], seven compared PD [18,19,24,25,27–29], and seven compared BOP [18,20,24,25,27–29] between participants with and without diabetes.

#### Marginal bone loss

In this study, a fixed effects model was used to evaluate MBL in patients with diabetes because of low heterogeneity between studies (p = .47,  $l^2 = 0\%$ ). Implant marginal bone loss was higher among patients with diabetes compared to healthy patients, and the difference was statistically significant. The MD of MBL in comparison between diabetes and patients without diabetes was 0.15 (95% CI = 0.10, 0.20; p < .00001) (Figure 2).

## Probing depth

The pooled effect size from all evaluated studies showed significant differences in PD between participants with and without diabetes mellitus (MD: 0.30; 95% CI 0.08, 0.51; p = .007). However, heterogeneity was high between studies (p < .00001,  $l^2 = 78\%$ ). To determine the possible sources of heterogeneity, we performed a subgroup analysis based on loading time (delayed loading, immediate loading and other) and HbA1c levels (6.1–8.0%, 8.1–10.0%,  $\geq$ 10.0%) (Figure 3).

## Bleeding on probing

We also compared BOP around the implants in patients with and without diabetes, and found that BOP in the control group was better than that in the diabetes mellitus group; this difference was statistically significant (MD: 22.62; 95% CI 16.82, 28.43; p < .00001). As the heterogeneity among studies was high, we conducted a similar subgroup analysis of the included studies for BOP as for PD; that is, we examined loading time (delayed loading, immediate loading and other) and HbA1c levels (6.1–8.0%, 8.1–10.0%,  $\geq$ 10.0%) (Figure 4).

#### **Publication bias**

Egger's regression test was used to analyse whether there was publication bias in each of the studies for the three different outcome indicators. The results showed that there was no significant publication bias in the studies of MBL (p = .146) or BOP (p = .558); however, there was possible publication bias in the studies of PD (p = .002).

## Discussion

This review was designed to evaluate the dental implant complications of MBL, PD and BOP between participants with and without diabetes mellitus. We found that there were significant differences in MBL between patients with and without diabetes. Three studies [21,24,25] showed that

Abdulaziz (2019)         BA         Saudi Arabia         3y         DM (26.5%)         119         52.7         65           Cobrera-Dominguez (2019)         PA         Spain         2y         DM (>6.6%)         28         56.75         NR           Al-Sowygh (2018)         RA         Saudi Arabia         NA         DM (>26.6%)         79         43.1         NR           Al-Sowygh (2018)         RA         Saudi Arabia         NA         DM (>26.6%)         70         54.6         59           Al Zahrani (2018)         PA         Saudi Arabia         7V         DM (>56.6%)         70         54.6         59           Al Zahrani (2016)         PA         Saudi Arabia         2y         DM (81-10%)         91         50.5         NR           Aguilar (2016)         PA         Spain         2y         DM (81-10%)         85         61         22           Gémez-Moreno (2015)         PA         Turkey         Iy         DM (=216%)         44/41         57         30           MoDM (<56%)         33/24         62         11         DM (81-10%)         83/24         62         11           Gémez-Moreno (2015)         PA         America         1y         DM (61-6%)	Author (Year)	Study design	Country	Follow up	Study group (HbA1c)	Subjects M/F	Mean age	Implant placed
Preum (S2-6.4%)         70/43         46.1         78           Cabren-Domínguez (2019)         PA         Spain         2y         DM (-5.6%)         28         56.75         NR           Al-Sowygh (2018)         RA         Saudi Arabia         NA         DM (-5.6%)         12/16         31         NR           Al Zahrani (2018)         PA         Saudi Arabia         7y         DM (-5.6%)         12/16         46.6         59           Al Amri (2016)         PA         Saudi Arabia         7y         DM (6.1-9%)         91         50.5         NR           Aguilar (2016)         PA         Saudi Arabia         2y         DM (6.1-9%)         91         50.5         NR           Aguilar (2016)         PA         Spain         2y         DM (6.1-9%)         44/41         57         30           redogan (2015)         PA         Turkey         1y         DM (6.1-9%)         67         64         11           DM (6.1-9%)         67         64         11         DM (8.1-10%)         33/24         62         11           DM (6.1-9%)         67         64         11         DM (8.1-10%)         33/24         62         11           DM (6.1-9%)	Abdulaziz (2019)	RA	Saudi Arabia	Зу	DM (≧6.5%)	119	52.7	65
RODM (4-3%)         24         5.2           Al-Sowygh (2018)         BA         Spain         2y         DM (5-60%)         12/16           Al-Sowygh (2018)         BA         Saudi Arabia         NA         DM (5-60%)         79         43.1         NR           Al Zahrani (2018)         PA         Saudi Arabia         NA         DM (5-60%)         70         54.6         59           Al Amri (2016)         PA         Saudi Arabia         2y         DM (5-60%)         70         54.6         59           Aguilar (2016)         PA         Saudi Arabia         2y         DM (5-1%)         85         61         22           Gorez-Moreno (2015)         PA         Spain         2y         DM (6-1%)         85         61         22           Gómez-Moreno (2015)         PA         Turkey         1y         DM (6-75%)         A4         52.6         22         11           DM (61-8%)         60         21         11         DM (61-8%)         60         21         11           DM (61-8%)         60         21         11         DM (61-8%)         60         21         11           DM (61-8%)         60         21         10         21/2 <td></td> <td></td> <td></td> <td></td> <td>PreDM (5.7–6.4%)</td> <td>/6/43</td> <td>46.1</td> <td>/8</td>					PreDM (5.7–6.4%)	/6/43	46.1	/8
Labrera-Johnniguez (2019) PA Spain 2/2 DM (5-6.0%) 2216 Al-Sowygh (2018) RA Saudi Arabia NA DM (26.5%) 79 43.1 NR NODM (26.6%) 79 43.1 NR Al-Sowygh (2018) PA Saudi Arabia 7/2 DM (26.6%) 70 54.6 59 NODM (26.6%) 46/2/4 46.8 59 NODM (26.6%) 46/2/4 46.8 59 NODM (26.6%) 46/2/4 46.8 59 NODM (26.6%) 91/0 50.0 NR DM (8.1-10%) 81 50.5 NR DM (8.1-10%) 85 61 22 DM (8.1-10%) 85 61 12/12 495 221 Tatarakis (2014) PA America 1y MBUM (self*eport) 12/12 495 21 NODM (self*eport) 12/12 495 22 NODM (self*eport) 15/15 56.05 36 36 NE Mean (5D) Dept(mm) Probing (9) Ad% 059 (14) 223 (153) 42 (2707) Ad% 059 (13) 218 (23) (2708) Ad% 059 (13) 218 (23) (2708) Ad% 059 (13) 218 (23) (2708) Ad% 059 (13) 224 (05) 2		54	c .	2	NoDM (4–5%)	20	43.4	52
Al-Sowygh (2018)         PA         Saudi Arabia         NA         DM (c=65%)         '''         ''''         43.1         NR           Al Zahrani (2018)         PA         Saudi Arabia         7y         DM (c=60%)         70         54.6         59           Al Zahrani (2016)         PA         Saudi Arabia         7y         DM (c=60%)         46/24         46.8         59           Aguilar (2016)         PA         Saudi Arabia         2y         DM (8.1–10%)         91         50.5         NR           Aguilar (2016)         PA         Spain         2y         DM (6.1–8%)         91/0         50.1           Aguilar (2015)         PA         Turkey         1y         DM (c=7.5%)         24         52.6         22           Gómez-Moreno (2015)         PA         Spain         3y         DM (c=10%)         33/34         62         11           DM (6.1–8%)         93/34         62         11         DM (6.1–8%)         59         24           Gómez-Moreno (2015)         PA         America         1y         DM (ceffreport)         12/12         49.5         21           Gómez-Moreno (2015)         PA         America         1y         DM (ceffreport)         15/15<	Cabrera-Dominguez (2019)	РА	Spain	2у	DM (>6.0%) NoDM (≤6.0%)	28 12/16	56./5	NR
NoDM (self-report)         79/0         44.2           A Zahrani (2018)         PA         Saudi Arabia         7y         DM (56.0%)         70         54.6         59           Al Amri (2016)         PA         Saudi Arabia         2y         DM (61-8%)         91         50.5         NR           Aguilar (2016)         PA         Spain         2y         DM (81-10%)         85         61         22           Gonga (2015)         PA         Spain         2y         DM (81-10%)         85         61         22           Gómez-Moreno (2015)         PA         Turkey         1y         DM (81-76%)         24         52.6         222           Gómez-Moreno (2015)         PA         America         1y         DM (81-76%)         59         24           MoDM (self-report)         32/4         62         11         DM (81-76%)         59         24           Tatarakis (2014)         PA         America         1y         DM (81-76%)         33/34         62         17           Bignozzi (2013)         PA         Roma         2y         DM (81-76%)         50         53         53         55         36           Cotrera-Dominguez (2019)         7.9%	Al-Sowygh (2018)	RA	Saudi Arabia	NA	DM (≧6.5%)	79	43.1	NR
Al Zahrani (2018) PA Saudi Arabia 7y DM (>6.0%) 70 54.6 59 NOM (≤6.0%) 46.724 46.8 59 NOM (≤6.0%) 910 50.1 NODM (<6.0%) 910 50.1 NODM (<6.0%) 44.7 Superior (2016) PA Spain 2y DM (8.1–10%) 85 61 222 DM (6.1–8%) 94.0 57 30 NOM (≤6.0%) 44.7 57 30 NOM (≤6.0%) 67 64 11 DM (6.1–8%) 99 233 Erdogan (2015) PA Spain 3y DM (≅1.0%) 37.34 62 111 DM (6.1–8%) 33.34 62 111 DM (6.1–8%) 59 24 NOM (≤6.0%) 59 24 NOM (50 24 22.0%) 50 24 24 20.2% 20 24 22.0% 24 NOM (50 24 24.0%) 59 24 NOM (50 24.0%) 50 24 24 20.0% 24 20.0% 24 NOM (50 24.0%) 50 24 24 20.0% NR 0.3 (1.3) 21 (4.3,4 24 27.0%) Al-Sovygh (2018) 10.2% NR NR 0.23 (0.45) 53 (56.4) Al-Sovygh (2018) 10.2% NR NR 0.23 (0.15) 62 7.0 Al-Armi (2018) 4.5% 0.5% (0.21) 2.3 (0.15) 62 7.0 Al-Armi (2018) 4.5% 0.5% (0.21) 2.3 (0.15) 62 7.0 Al-Armi (2018) 4.5% 0.4% (0.16) 1.6 (0.05) 44 (40.21) Al-Armi (2016) NR 0.37 (0.63) 2.40 (0.83) 72 (1.95) C.6.4% 0.58 (0.15) 2.3 (0.15) 62 7.0 Al-Armi (2018) NR 0.37 (0.63) 2.40 (0.83) 72 (1.95) C.6.4% 0.58 (0.15) 2.3 (0.15) 62 7.0 Al-Armi (2018) NR 0.37 (0.63) 2.40 (0.83) 72 (1.95) C.6.4% 0.58 (0.15) 2.3 (0.15) 62 7.0 Al-Armi (2018) NR 0.37 (0.63) 2.40 (0.83) 72 (1.95) C.6.4% 0.59 (0.21) 2.28 (0.80) 74 (2.45) C.7.9 (2.45) 2.26 (0.80) 44 (40.21) C.7.9 (2.45) 2.26 (0.80) 44 (40.21) C.7.9 (2.45) 2.26 (0.80) 44 (40.21) C.7.9 (2.45) 2.26 (0.81) 74 (2.45) C.7.9 (2.45) 2.26 (0.81) 74 (2					NoDM (self-report)	79/0	44.2	
Al Amri (2016) PA Saudi Arabia 2y DM (8.1–10%) 91 50.5 NR Aguilar (2016) PA Spain 2y DM (8.1–10%) 91 50.5 NR Aguilar (2016) PA Spain 2y DM (8.1–10%) 85 61 22 Endegan (2015) PA Turkey 1y DM (6.7–8%) 44/41 57 30 NDDM (6.6%) 44/41 57 30 NDDM (6.6%) 459 33 Endegan (2015) PA Turkey 1y DM (6.7–5%) 24 52.6 222 NDDM (8.1–10%) 33/34 62 111 DM (8.1–10%) 33/34 62 131 Endersent 2015) PA America 1y DM (8.1–10%) 33/34 62 131 Tatarakis (2014) PA America 1y DM (6.1–6%) 59 244 NoDM (6.1–6%) 59 24 NoDM (6.1–6%) 59 24 NOM (6.1–6%) 59 24 N	Al Zahrani (2018)	PA	Saudi Arabia	7у	DM (>6.0%)	70	54.6	59
Al Amn (2016) PA Saudi Arabia 2/y DM (81-10%) 91 50.5 NN M (-7%) 91/0 50.1 NoDM (-6%) 48.5 Aguilar (2016) PA Spain 2/y DM (81-10%) 85 61 22 DM (61-8%) 44/41 57 30 NODM (=6%) 59 33 Erdogan (2015) PA Turkey 1/y DM (6-7.5%) 24 52.6 222 NoDM (=6%) 67 64 11 DM (81-10%) 67 64 11 DM (81-10%) 67 64 11 DM (81-10%) 63/34 62 11 DM (81-10%) 73% 0.55.13 15 NoDM (self-report) 30 55.13 15 Advitor (Year) Mean (5D) Mean (5D) Mean (5D) Mean (5D) Mean (5D) Mean (5D) Advitor (Year) Mean (5D) Mean (5D) Mean (5D) Advitor (Year) NR 0.59 (1.41) 2.23 (1.45) 51 (2.3 (7.9) Ad-6% 0.59 (1.41) 2.23 (1.45) 27 (1.5) Advitor (218) A2% NR NR 0.23 (7.9) Ad-6% 0.59 (0.21) 2.3 (0.62) 62 (5.0) Advitor (2018) A2% NR NR 0.23 (7.9) Advitor (2018) A2% NR NR 0.23 (7.9) Advitor (2018) A2% 0.58 (0.7) 2.13 (0.68) 2.7 (1.55) Advitor (219) Advitor (2018) A2% NR NR 0.23 (0.5) Advitor (219) Advitor (2018) A2% 0.58 (0.7) Advitor (218) A2% 0.58 (0.7) Advitor (218) A2% 0.58 (0.7) Advitor (218) A2% 0.58 (0.7) Advitor (218) A2% 0.58 (0.7) Advitor (219) Advitor (218) A2% 0.58 (0.7) Advitor (219) Advitor (219) Advitor (219) Advitor (219) Advitor (219) Advitor (219) Advitor (2015) A7% 0.038 (0.25) 2.24 (0.83) Advitor (219) Advitor (219) Advitor (219)					NoDM (≦6.0%)	46/24	46.8	59
Aguilar (2016) PA Spain 2y DM (6-1-8%) 9/1/0 50.1 NoDM (<6%) 48.5 DM (6-1-8%) 44/41 57 30 NoDM (≦6%) 59 33 Erdogan (2015) PA Turkey 1y DM (6-7.5%) 24 52.6 22 NoDM (56/Feport) 12/12 49.5 21 DM (6.1-8%) 33/3/4 62 11 DM (8.1-10%) 59 24 NoDM (56/Feport) 12/12 49.5 21 Comez-Moreno (2015) PA Spain 2y DM (56/Feport) 16/16 64 41 Bignozzi (2013) PA Roma 2y DM (56/Feport) 16/16 64 41 Bignozzi (2013) PA Roma 2y DM (56/Feport) 15/15 56.05 36 Comez-Moreno (2015) 7.7% 0.69 (1.37) 2.39 (1.45) 53 (56.05 36 Addulaziz (2019) 7.9% 0.69 (1.37) 2.39 (1.45) 53 (56.05 36 Addulaziz (2019) 7.9% 0.69 (1.37) 2.39 (1.45) 53 (56.05 36 Addulaziz (2019) 7.9% 0.69 (1.37) 2.39 (1.45) 53 (56.05 36 Addulaziz (2019) 7.9% 0.69 (1.37) 2.39 (1.45) 53 (56.05 36 Addulaziz (2019) 6.64% 0.65 (1.13) 2.18 (1.3) 21 (4.30) NR Al-Sowygh (2018) 10.22% NR NR NR 0.53 (1.31) 2.18 (1.3) 21 (4.30) 2.14 (4.02.1) Addulaziz (2019) 6.64% 0.58 (0.57) 2.13 (0.68) NR Al-Sowygh (2018) 10.22% NR NR 0.58 (0.70) A Al-Sowygh (2018) 8.2% 1.1 (0.81) NR 0.78 (2.3 (0.5) 40 (6.0) Addulaziz (2016) NR 0.58 (0.67) 2.13 (0.65) 40 (6.0) Advis 0.59 (0.41) 2.33 (0.51) 6.27 (0.78) Al-Sowygh (2018) 8.2% 1.1 (0.81) NR 0.78 (0.49) 2.27 (0.78) Al-Sowygh (2018) NR 0.58 (0.67) 2.3 (0.51) 6.27 (0.79) Advis 0.58 (0.70) A Al-Amri (2016) 8.7% 0.58 (0.70) A Al-Amri (2016) 8.7% 0.58 (0.70) A Al-Amri (2016) NR 0.58 (0.51) 2.3 (0.51) 6.27 (7.0) Advis 0.59 (0.62) 2.40 (0.83) 7.2 (1.59) 0.67 (0.78) 2.26 (0.87) 7.4 (2.43) 0.96 (1.48) 2.79 (1.13) 51 (2.23) 0.57 (0.78) 2.26 (0.87) 7.4 (2.44) 0.57 (0.78) 2.26 (0.87) 7.4 (2.45) 0.56 (0.78) 2.25 (0.87) 7.4 (2.45) 0.56 (0.78) 2.25 (0.87) 7.4 (2.45) 0.57 (0.78) 2.25 (0.87) 7.4 (2.45) 0.56 (0.78) 2.25 (0.87) 7.4 (2.45) 0.57 (0.78) 2.25 (0.87) 7.4 (2.5	Al Amri (2016)	PA	Saudi Arabia	2y	DM (8.1–10%)	91	50.5	NR
Aguilar (2016)         PA         Spain         2y         DM (1         Mount (         Mount					DM (6.1-8%)	91/0	50.1	
Aguilar (2016) PA Spain 2/2 DM (6.1–8%) 6.3 0.1 2/2 DM (6.1–8%) 44/41 57 30 NDDM (≤6%) 59 33 Gémez-Moreno (2015) PA Turkey 10 DM (6-7.5%) 24 52.6 22 NDDM (≤1-6%) 67 64 11 DM (8.1–8%) 33/34 62 111 DM (8.1–10%) 33/34 62 111 DM (8.1–8%) 59 24 NDDM (≤10%) 67 64 11 DM (8.1–8%) 59 24 NDDM (≤6%) 60 21 Tatarakis (2014) PA America 1y DM (self-report) 16/16 64 41 Bignozzi (2013) PA Roma 2/ DM (self-report) 16/16 64 41 Bignozzi (2013) PA Roma 2/ DM (self-report) 15/15 56.05 36 HbA1C MBL (nm) Probing Bleeding on (baseline) Mean (SD) Depth (mm) Probing (%) Author (Year) 46% 0.59 (1.41) 2.23 (1.85) 42 (70.7) Abdulaziz (2019) 7.9% 0.69 (1.37) 2.39 (1.45) 53 (56.4) 6.4% 0.59 (1.41) 2.23 (1.85) 42 (70.7) Abdulaziz (2019) 7.9% 0.69 (1.37) 2.39 (1.45) 53 (56.4) A6.4% 0.59 (1.41) 2.23 (1.85) 42 (70.7) Abdulaziz (2019) 6.64% 0.68 (0.67) 2.13 (0.68) NR Al-Sowygh (2018) 10.2% NR NR 62.3 (7.9) Al-Sowygh (2018) 42% 1.1 (0.81) NR NR Al-Sowygh (2018) 42% 1.1 (0.81) NR Al-Sowygh (2018) 42% 1.1 (0.81) NR Al-Sowygh (2018) 42% 1.1 (0.81) NR Al-Sowygh (2016) 42% NR NR NR 62.3 (7.9) Al-Anmi (2016) 8.2% 1.1 (0.81) NR NR 0.58 (0.70) Al Anmi (2016) 8.2% 1.11 (0.81) NR NR Al-Sowygh (2015) 6.7% 1.33 (0.15) 62 (7.0) Al Anmi (2016) 8.2% 0.59 (0.2) 2.3 (0.62) 62 (5.0) 6.8% 0.58 (0.70) Al Anmi (2016) NR 0.98 (0.15) 2.3 (0.15) 62 (7.0) Al Anmi (2016) NR 0.98 (0.15) 2.3 (0.15) 62 (7.0) Al Anmi (2016) NR 0.98 (0.15) 2.3 (0.15) 62 (7.0) Al Anmi (2016) NR 0.98 (0.15) 2.3 (0.15) 62 (7.0) Al Anmi (2016) NR 0.98 (0.15) 2.3 (0.62) 62 (5.0) Aguilar (2015) 6.7% 1.13 (0.31) NR NR NR 0.93 (0.31) Gómez-Moreno (2015) NR 0.98 (0.25) 2.24 (0.83) 7.7 (1.99) ANR 0.93 (0.31) Gómez-Moreno (2015) NR 0.93 (0.31) Softwo 0.70 (0.78) 2.20 (0.89) 54 (2.44) Softwo 0.56 (0.73) 2.20 (0.89) 54 (4.402.21) Softwo 0.57 (0.78) 2.20 (0.89) 54 (4.402.21) Softwo 0.57 (0.78) 2.20 (0.89) 55 (5.25.46) Bignozzi (2013) 505% 0.07 (0.12) 2.28 (0.031) 31 (14.0)	Aquillar (2016)	DA	Curain	2	NODM (<6%)	05	48.5	22
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Aguilar (2016)	PA	Spain	2у	DM (8.1-10%)	85	61	22
Erdogan (2015)         PA         Turkey         IV         NoDM (5-75%)         24         52.6         22           Gómez-Moreno (2015)         PA         Spain         3y         DM (210%)         67         64         11           DM (210%)         67         64         11         DM (3-10%)         59         24           Gómez-Moreno (2015)         PA         Spain         3y         DM (210%)         65         27           Tatarakis (2014)         PA         America         1y         DM (self-report)         32         65         27           Tatarakis (2013)         PA         Roma         2y         DM (self-report)         16/16         64         41           Bignozzi (2013)         PA         Roma         2y         DM (self-report)         130         55.13         15           Mobulaziz (2013)         PA         Roma         2y         DM (self-report)         130         55.13         15           Author (Year)         Mean (SD)         Depth (mm)         Probing         Bleeding on         Mean (SD)           Advitor (Year)         7.9%         0.69 (1.37)         2.39 (1.45)         53 (56.4)           Advitor (Year)         6.64%         0.					DM (6.1-8%)	44/41	57	30
Erdogan (2015) PA lurkey iy DM (5-75%) 24 52.6 22 NoDM (self-report) 12/12 49.5 21 Gómez-Moreno (2015) PA Spain 3y DM (210%) 67 64 11 DM (8.1-10%) 33/34 62 11 DM (8.1-9%) 59 24 NoDM (self-report) 32 65 27 NoDM (self-report) 32 65 27 NoDM (self-report) 30 55.13 15 NoDM (self-report) 15/15 56.05 36 Athor (Year) Mean (SD) Mean (SD) Adulaziz (2019) 7.9% 0.69 (1.37) 2.39 (1.45) 42 (70.7) Athor (Year) New 0.59 (0.67) 2.13 (0.68) NR Arbor (Year) 4.4% 0.75 (0.49) 2.07 (0.78) Al-Sowygh (2018) 10.2% NR NR 62.3 (7.9) Al-Sowygh (2018) 8.2% 1.1 (0.81) NR 62.3 (7.9) Al-Sowygh (2018) 8.2% 0.15 2.3 (0.62) 42 (5.0) Al-Armi (2016) 8.7% 0.58 (0.70) Al Armi (2016) NR 0.58 (0.15) 2.3 (0.15) 2.47 (0.34) NR 0.98 (1.48) 2.79 (1.31) 51 (27.9) 0.72 (1.75) 2.67 (0.80) 44 (40.21) Erdogan (2015) 6.7% 1.13 (0.31) NR NR NR Gómez-Moreno (2015) NR 0.7% 0.39 (0.2) 2.30 (0.33) 72 (19.9) 0.57 (0.78) 2.26 (0.87) 45 (2.49) 0.57 (0.49) 0.58 (0.2) 2.26 (0.87) 45 (2.40) 0.59 (0.78) 0.28 (0.25) 2.26	Full	DA	Tankan	1	NODM (≧6%)	24	59	33
Gómez-Moreno (2015)         PA         Spain         3y         DMM (≅10%)         67         64         11           DM (≅10%)         57         64         11           DM (§1-10%)         33/34         62         11           Bignozzi (2013)         PA         America         19         DM (§1-report)         30         55.13         15           MoDM (self-report)         15/15         56.05         36           Author (Year)         Mean (SD)         Depth (nm)         Probing (%)         64         47           Abdulaziz (2019)         7.9%         0.69 (1.37)         2.39 (1.45)         33 (56.4)           Cabrera-Domínguez (2019)         6.64%         0.58 (1.41)         2.23 (1.85)         42 (70.7)           Al-Sowych (2018)         10.2%         NR         NR         62.3 (7.9)           Al-Sowych (2018)         10.2%         NR	Erdogan (2015)	PA	Turkey	Iy	DM(6-7.5%)	24	52.6	22
Gomez-Moreno (2015)         PA         Spain         Sy         DM (8,1−10%)         33/34         62         11           DM (8,1−10%)         33/34         62         11         DM (8,1−10%)         33/34         62         11           Tatarakis (2014)         PA         America         1y         DM (8,1−10%)         33/34         62         21           Bignozzi (2013)         PA         America         1y         DM (self-report)         30         55,13         15           MoDM (self-report)         15/15         56.05         36           HbA1c         MBL (mm)         Probing         Bleeding on         Mean (5D)         Mean (5D)         Mean (5D)           Author (Year)         7.9%         0.69 (1.37)         2.39 (1.45)         53 (56.4)         6.4%         0.59 (1.41)         2.23 (1.85)         42 (70.7)           Abdulaziz (2019)         7.9%         0.66 (0.67)         2.13 (0.68)         NR         NR         247 (9.5)           Al-Sowygh (2018)         10.2%         NR         NR         247 (9.5)         42 (70.7)           Al-Sowygh (2018)         10.2%         NR         NR         247 (9.5)         42 (70.7)           Al-Sowygh (2018)         10.2%	Cám - Managa (2015)	DA	Curreiu	2	NoDM (self-report)	12/12	49.5	21
DMI (6.1–0%)         53/34         62         11           DMI (6.1–0%)         59         24           NODM (51–0%)         60         21           Tatarakis (2014)         PA         America         1y         DMI (61–8%)         60         21           Bignozzi (2013)         PA         Roma         2y         DMI (self-report)         30         55.13         15           MoDM (self-report)         30         55.13         15         NoDM (self-report)         30         55.13         15           Author (Year)         MBa (SD)         Depth (mm)         Probing         Bleeding on (baseline)         Mean (SD)         Mean (SD)         Mean (SD)           Author (Year)         6.4%         0.59 (1.41)         2.23 (1.45)         53 (56.4)           Cabrera-Domínguez (2019)         6.64%         0.68 (0.67)         2.13 (0.68)         NR           Al-Sowygh (2018)         10.2%         NR         NR         62.3 (7.9)           Al-Sowygh (2018)         10.2%         NR         NR         62.3 (7.9)           Al-Amri (2016)         8.7%         0.58 (0.70)         -         A           Author (2016)         8.7%         0.59 (0.2)         2.3 (0.62)         62 (5.0) <td>Gomez-Moreno (2015)</td> <td>PA</td> <td>Spain</td> <td>Зу</td> <td>DM (≦10%)</td> <td>6/</td> <td>64</td> <td>11</td>	Gomez-Moreno (2015)	PA	Spain	Зу	DM (≦10%)	6/	64	11
Durble (1-9%)         59         24           NoDM (≤el6%)         60         21           Tatarakis (2014)         PA         America         1y         DM (self-report)         32         65         27           Bignozzi (2013)         PA         Roma         2y         DM (self-report)         30         55.13         15           MoDM (self-report)         30         55.13         15         36           HbA1c         MBL (mm)         Probing         Bleeding on           (baseline)         Mean (SD)         Depth (mm)         Probing (%)           Addulaziz (2019)         7.9%         0.69 (1.37)         2.39 (1.45)         53 (56.4)           Ade%         0.51 (1.3)         2.13 (1.65)         42 (70.7)         4.6%         0.51 (1.3)         2.13 (0.68)         NR           Cabrea-Domínguez (2019)         6.64%         0.68 (0.67)         2.13 (0.68)         NR         42.7 (9.5)           Al-Sowygh (2018)         10.2%         NR         NR         62.3 (7.9)         2.47 (9.5)           Al Amri (2016)         8.7%         0.59 (0.2)         2.3 (0.62)         62 (5.0)           Al Amri (2016)         NR         1.92 (1.78)         3.68 (2.25)         74 (23.45)					DM (8.1-10%)	33/34	62	11
Tatarakis (2014)         PA         America         Iy         DM (self-report)         32         65         27           Bignozzi (2013)         PA         Roma         2y         DM (self-report)         16/16         64         41           Bignozzi (2013)         PA         Roma         2y         DM (self-report)         15/15         56.05         36           HbA1c         MEan (SD)         Depth (mm)         Probing         Bleeding on (baseline)           Author (Year)         Mean (SD)         Mean (SD)         Mean (SD)         Mean (SD)         Mean (SD)           Author (Year)         6.4%         0.59 (1.41)         2.23 (1.85)         42 (70.7)           Abdulaziz (2019)         7.9%         0.69 (1.37)         2.39 (1.45)         53 (56.4)           Cabrera-Domínguez (2019)         6.64%         0.68 (0.67)         2.13 (0.68)         NR           Al-Sowygh (2018)         10.2%         NR         NR         247 (9.5)           Al-Zahrani (2018)         8.2%         1.1 (0.81)         NR         247 (9.5)           Al Amri (2016)         8.7%         0.59 (0.2)         2.3 (0.62)         62 (5.7)           Of Z2 (1.55)         2.67 (0.80)         44 (40.21)         7.4 (23.45)					DM (6.1-8%)		59	24
Iataraks (2014)         PA         America         Iy         Um (self-report)         32         bs         bs         2//           Bignozzi (2013)         PA         Roma         2y         DM (self-report)         30         55.13         15           Bignozzi (2013)         PA         Roma         2y         DM (self-report)         30         55.13         15           HbA1c         MBL (mm)         Probing         Bleeding on (baseline)         Mean (SD)         Depth (mm)         Probing (%)           Author (Year)         7.9%         0.69 (1.37)         2.39 (1.4S)         53 (56.4)           Abdulaziz (2019)         7.9%         0.69 (1.37)         2.39 (1.4S)         427 (70.7)           Cabrera-Domínguez (2019)         6.4%         0.51 (1.3)         2.18 (1.3)         21 (43.4)           Cabrera-Domínguez (2019)         5.19%         0.75 (0.49)         2.07 (0.78)         PA           Al-Sowygh (2018)         10.2%         NR         NR         62.3 (7.9)           Al Zahrani (2016)         8.7%         0.58 (0.70)         A         A           Al Amri (2016)         8.7%         0.58 (0.15)         2.3 (0.62)         62 (5.0)           Gámez-Moreno (2015)         NR         1.92 (	T-t	DA	A	1	NODM (≧6%)	22	60	21
Bignozzi (2013)         PA         Roma         Zy         DM (self-report) NoDM (self-report)         15 / 15         64         4 / 4           Bignozzi (2013)         PA         Roma         Zy         DM (self-report)         15 / 15         56.05         36           HbA1c         MBL (mm)         Probing         Bleeding on (baseline)         Bleeding on Mean (SD)         Mean (SD)         Mean (SD)           Author (Year)         7.9%         0.69 (1.37)         2.39 (1.45)         53 (56.4)           Abdulaziz (2019)         7.9%         0.69 (1.37)         2.39 (1.45)         53 (56.4)           Cabrera-Domínguez (2019)         6.64%         0.51 (1.3)         2.18 (1.3)         2.1 (43.4)           Cabrera-Domínguez (2019)         6.64%         0.68 (0.67)         2.13 (0.68)         NR           Al-Sowygh (2018)         10.2%         NR         NR         62.3 (7.9)           Al Zahrani (2018)         8.2%         1.1 (0.81)         NR         24.7 (9.5)           Al Armi (2016)         8.7%         0.59 (0.2)         2.3 (0.62)         62 (5.0)           Again (2016)         NR         1.92 (1.78)         3.68 (2.25)         74 (23.45)           Again (2016)         NR         0.92 (1.48)         2.79 (1.31) <td>Tatarakis (2014)</td> <td>PA</td> <td>America</td> <td>Iy</td> <td>DM (self-report)</td> <td>32</td> <td>65</td> <td>27</td>	Tatarakis (2014)	PA	America	Iy	DM (self-report)	32	65	27
Bighozzi (2013)         PA         Roma         Zy         NobM (self-report)         3:0         3:5:1:3         15           NobM (self-report)         15/15         56:05         36           HbA1c         MBL (mm)         Probing         Bleeding on           Author (Year)         Mean (SD)         Depth (mm)         Probing (%)           Abdulaziz (2019)         7.9%         0.69 (1.37)         2.39 (1.45)         53 (56.4)           Cabrera-Domínguez (2019)         6.64%         0.51 (1.3)         2.18 (1.3)         21 (4.5)           Cabrera-Domínguez (2019)         6.64%         0.68 (0.67)         2.13 (0.68)         NR           Al-Sowygh (2018)         10.2%         NR         NR         62.3 (7.9)           Al-Sowygh (2018)         10.2%         NR         NR         0.58 (0.70)           Al Armi (2016)         8.7%         0.58 (0.70)         4.4%         24.7 (9.5)           Al Armi (2016)         8.7%         0.58 (0.70)         4.44%         2.79 (1.31)         51 (27.39)           Aguilar (2016)         8.7%         0.59 (0.2)         2.3 (0.62)         62 (5.0)         6.6%         0.58 (0.15)         2.3 (0.15)         62 (7.0)           Aguilar (2016)         8.7	Diana	DA	Dama	2	NODM (self-report)	16/16	64	41
Nubber (Self-report)         15/15         350.05         36           HbA1c         MBL (mm)         Probing         Bleeding on           Author (Year)         Mean (SD)         Depth (mm)         Probing (%)           Abdulaziz (2019)         7.9%         0.69 (1.37)         2.39 (1.45)         53 (56.4)           Abdulaziz (2019)         6.4%         0.59 (1.41)         2.23 (1.85)         42 (70.7)           4.6%         0.51 (1.3)         2.18 (1.3)         21 (43.4)           Cabrera-Domínguez (2019)         6.64%         0.68 (0.67)         2.13 (0.68)         NR           Al-Sowygh (2018)         10.2%         NR         NR         62.3 (7.9)           Al-Sowygh (2018)         10.2%         NR         NR         62.2 (7.0)           Al-Sowygh (2018)         8.2%         1.1 (0.81)         NR         9.2 (7.0)           Al-Sowygh (2016)         8.7%         0.59 (0.2)         2.3 (0.62)         62 (5.0)           Al-Sowygh	Bignozzi (2013)	PA	кота	2у	Divi (seit-report)	30	55.13	15
HbA1c (baseline)         MBL (mm) Mean (SD)         Probing Depth (mm) Mean (SD)         Bleeding on Probing (%) Mean (SD)           Author (Year)         7.9%         0.69 (1.37)         2.39 (1.45)         53 (56.4)           Abdulaziz (2019)         7.9%         0.69 (1.37)         2.39 (1.45)         53 (56.4)           Cabera-Domínguez (2019)         6.64%         0.51 (1.3)         2.18 (1.3)         21 (43.4)           Cabera-Domínguez (2019)         6.64%         0.68 (0.67)         2.13 (0.68)         NR           Al-Sowygh (2018)         10.2%         NR         NR         24.7 (9.5)           Al-Sowygh (2018)         10.2%         NR         NR         24.7 (9.5)           Al Zahrani (2018)         8.2%         1.1 (0.81)         NR         NR           Al Amri (2016)         8.7%         0.59 (0.2)         2.3 (0.62)         62 (5.0)           Al Amri (2016)         NR         1.92 (1.78)         3.66 (2.25)         74 (23.45)           Aguilar (2016)         NR         1.92 (1.78)         3.66 (2.25)         74 (23.45)           MR         0.93 (0.31)         0.44 (0.20)         74 (23.45)         72 (19.9)           MR         0.93 (0.31)         0.57 (0.78)         2.30 (1.13)         56 (34.3)					NODW (sell-report)	15/15	50.05	50
Mean (SD)         Depth (mm) (Mean (SD)         Probing (%) (Mean (SD)           Author (Year)         7.9%         0.69 (1.37)         2.39 (1.45)         5.3 (56.4)           Abdulaziz (2019)         6.6%         0.59 (1.41)         2.23 (1.85)         4.2 (70.7)           4.6%         0.51 (1.3)         2.18 (1.3)         21 (43.4)           Cabrera-Domínguez (2019)         6.64%         0.68 (0.67)         2.13 (0.68)         NR           Al-Sowygh (2018)         10.2%         NR         2.47 (9.5)         2.47 (9.5)           Al-Sowygh (2018)         10.2%         NR         2.47 (9.5)         2.47 (9.5)           Al-Sowygh (2018)         10.2%         NR         NR         2.47 (9.5)           Al-Sowygh (2018)         10.2%         NR         NR         2.47 (9.5)           Al-Sowygh (2018)         10.2%         NR         NR         6.2 (7.0)           Al-Sowygh (2018)         10.2%         0.58 (0.5)         2.3 (0.62)         6.2 (7.0)           Al-Sowygh (2018)         10.2%         0.58 (0.5)         2.3 (0.5)         6.2 (7.0)           Al-Sowygh (2018)         6.7%         0.58 (0.5)         2.3 (0.5)         6.2 (7.0)           Al-Mari (2016)         8.7%         0.59 (0.2)         2.			HbA1c	MBL (I	mm)	Probing		Bleeding on
Author (Year)         Mean (SD)         Mean (SD)         Mean (SD)           Abdulaziz (2019)         7.9%         0.69 (1.37)         2.39 (1.45)         53 (56.4)           6.4%         0.59 (1.41)         2.23 (1.85)         42 (70.7)           4.6%         0.51 (1.3)         2.18 (1.3)         21 (43.4)           Cabrera-Domínguez (2019)         6.64%         0.68 (0.67)         2.13 (0.68)         NR           Al-Sowygh (2018)         10.2%         NR         NR         62.3 (7.9)           Al-Sowygh (2018)         10.2%         NR         NR         62.3 (7.9)           Al-Sowygh (2018)         8.2%         1.1 (0.81)         NR         NR           Al-Zahrani (2018)         8.2%         0.59 (0.2)         2.3 (0.62)         62 (5.0)           Al Amri (2016)         8.7%         0.58 (0.70)         -         -           Al Amri (2016)         8.7%         0.58 (0.15)         2.3 (0.62)         62 (5.0)           6.8%         0.59 (0.2)         2.3 (0.62)         62 (5.0)         44 (40.2)           Gómez-Moreno (2015)         NR         1.92 (1.78)         3.68 (2.25)         74 (23.45)           Gómez-Moreno (2015)         NR         0.93 (0.31)         51 (27.5)		(k	oaseline)	Mean	(SD)	Depth (mm)		Probing (%)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Author (Year)					Mean (SD)		Mean (SD)
Cabrie (2017)         64%         0.59 (1.41)         2.23 (1.85)         42 (70.7)           4.6%         0.51 (1.3)         2.18 (1.3)         21 (43.4)           Cabrera-Domínguez (2019)         6.64%         0.68 (0.67)         2.13 (0.68)         NR           Al-Sowygh (2018)         10.2%         NR         NR         62.3 (7.9)           Al-Sowygh (2018)         10.2%         NR         NR         62.3 (7.9)           Al-Zahrani (2018)         8.2%         1.1 (0.81)         NR         R           Al-Zahrani (2016)         8.7%         0.58 (0.70)         2.3 (0.62)         62 (5.0)           Al Amri (2016)         8.7%         0.58 (0.15)         2.3 (0.15)         62 (7.0)           Aguilar (2016)         NR         1.92 (1.78)         3.68 (2.25)         74 (23.45)           0.72 (1.55)         2.67 (0.80)         44 (40.2)         0.72 (1.55)         2.67 (0.80)         44 (40.2)           6ómez-Moreno (2015)         NR         1.92 (1.78)         3.68 (2.25)         74 (23.45)           0.72 (1.55)         2.67 (0.80)         44 (40.21)         71 (23.45)         2.67 (0.80)         44 (40.21)           6ómez-Moreno (2015)         NR         0.70 (0.63)         2.40 (0.83)         72 (19.9)	Abdulaziz (2019)		7.9%	0.69	(1.37)	2.39 (1.45)		53 (56.4)
4.6%         0.51 (1.3)         2.18 (1.3)         21 (43.4)           Cabrera-Domínguez (2019)         6.64%         0.68 (0.67)         2.13 (0.68)         NR           Al-Sowygh (2018)         10.2%         NR         NR         62.3 (7.9)           Al-Sowygh (2018)         10.2%         NR         NR         62.3 (7.9)           Al-Zahrani (2018)         8.2%         1.1 (0.81)         NR         82.47 (9.5)           Al Zahrani (2016)         8.7%         0.59 (0.2)         2.3 (0.62)         62 (5.0)           Al Amri (2016)         8.7%         0.59 (0.2)         2.3 (0.62)         62 (5.0)           Aguilar (2016)         8.7%         0.59 (0.2)         2.3 (0.15)         62 (7.0)           Aguilar (2016)         NR         1.92 (1.78)         3.68 (2.25)         74 (23.45)           Aguilar (2016)         NR         1.92 (1.78)         3.68 (2.25)         74 (23.45)           Coff (21.5)         2.67 (0.80)         44 (40.21)         71.73           Frdogan (2015)         6.7%         1.13 (0.34)         NR         NR           0.57 (0.78)         2.30 (1.13)         56 (3.43)         72 (19.9)           0.53 (0.78)         2.26 (0.87)         65 (3.23)         62 (3.5)	()		6.4%	0.59	(1.41)	2.23 (1.85)		42 (70.7)
Cabrera-Domínguez (2019)         6.64%         0.68 (0.67)         2.13 (0.68)         NR           Al-Sowygh (2018)         10.2%         NR         NR         62.3 (7.9)           Al-Sowygh (2018)         10.2%         NR         NR         62.3 (7.9)           Al-Sowygh (2018)         10.2%         NR         NR         62.3 (7.9)           Al Zahrani (2018)         8.2%         1.1 (0.81)         NR         NR           Al-Sowygh (2018)         8.2%         1.1 (0.81)         NR         NR           Al Zahrani (2016)         8.7%         0.58 (0.70)         7.0         6.2 (7.0)           Al Amri (2016)         8.7%         0.59 (0.2)         2.3 (0.62)         62 (5.0)           As/s%         0.58 (0.15)         2.3 (0.15)         62 (7.0)         6.6 (7.0)           As/s%         0.46 (0.16)         1.6 (0.05)         40 (6.0)         6.0 (7.0)           Aguilar (2016)         NR         1.92 (1.78)         3.68 (2.25)         74 (23.45)           Cogan (2015)         6.7%         1.13 (0.34)         NR         NR           MR         0.93 (0.31)         0.72 (1.55)         2.67 (0.83)         72 (19.9)           Gómez-Moreno (2015)         NR         0.70 (0.63)			4.6%	0.51	(1.3)	2.18 (1.3)		21 (43.4)
Science Convergence (LTC)         Science (LTC)         Scien (LTC)         Science (LTC) <t< td=""><td>Cabrera-Domínguez (2019)</td><td></td><td>6.64%</td><td>0.68</td><td>(0.67)</td><td>2.13 (0.68)</td><td></td><td>NR</td></t<>	Cabrera-Domínguez (2019)		6.64%	0.68	(0.67)	2.13 (0.68)		NR
Al-Sowygh (2018)         10.2%         NR         NR         62.3 (7.9)           Al-Sowygh (2018)         1.02%         NR         24.7 (9.5)           Al Zahrani (2018)         8.2%         1.1 (0.81)         NR         NR           4.7%         0.58 (0.70)			5.19%	0.75	(0.49)	2.07 (0.78)		
Al Zahrani (2018)       4.4%       24.7 (9.5)         Al Zahrani (2018)       8.2%       1.1 (0.81)       NR       NR         4.7%       0.58 (0.70)       0.58 (0.70)       0.59 (0.2)       2.3 (0.62)       62 (5.0)         Al Amri (2016)       8.7%       0.59 (0.2)       2.3 (0.15)       62 (7.0)         6.8%       0.58 (0.15)       2.3 (0.15)       62 (7.0)         4.5%       0.46 (0.16)       1.6 (0.05)       40 (6.0)         Aguilar (2016)       NR       1.92 (1.78)       3.68 (2.25)       74 (23.45)         0.98 (1.48)       2.79 (1.31)       51 (27.39)       0.72 (1.55)       2.67 (0.80)       44 (40.21)         Erdogan (2015)       6.7%       1.13 (0.34)       NR       NR       NR         0.93 (0.31)       0.72 (1.55)       2.67 (0.80)       44 (40.21)         Erdogan (2015)       6.7%       1.13 (0.34)       NR       NR         0.64 (0.56)       2.34 (0.66)       62 (19.9)       65 (25.46)       62 (19.9)         0.67 (0.78)       2.30 (1.13)       56 (34.3)       72 (19.9)       65 (25.45)         0.57 (0.78)       2.35 (0.67)       67 (22.45)       5.7%       -0.08 (0.25)       2.20 (0.89)       56 (25.45)         Bigno	Al-Sowyah (2018)		10.2%	NR	()	NR		62.3 (7.9)
Al Zahrani (2018) 8.2% 1.1 (0.81) NR NR 4.7% 0.58 (0.70) Al Amri (2016) 8.7% 0.59 (0.2) 2.3 (0.62) 62 (5.0) 6.8% 0.59 (0.2) 2.3 (0.15) 62 (7.0) 4.5% 0.46 (0.16) 1.6 (0.05) 40 (6.0) Aguilar (2016) NR 1.92 (1.78) 3.68 (2.25) 74 (23.45) 0.98 (1.48) 2.79 (1.31) 51 (27.39) 0.72 (1.55) 2.67 (0.80) 44 (40.21) Erdogan (2015) 6.7% 1.13 (0.34) NR NR NR 0.93 (0.31) Gómez-Moreno (2015) NR 0.70 (0.63) 2.40 (0.83) 72 (19.9) 0.64 (0.56) 2.34 (0.66) 62 (19.9) 0.67 (0.78) 2.30 (1.13) 56 (34.3) 0.57 (0.78) 2.20 (0.87) 45 (27.5) Tatarakis (2014) 7.1% 0.19 (0.45) 2.35 (0.67) 67 (22.45) 5.7% -0.08 (0.25) 2.20 (0.89) 56 (25.46) Bignozzi (2013) 9.05% 1.07 (0.12) 2.81 (0.31) 31 (14.0)			4.4%					24.7 (9.5)
A7%       0.58 (0.70)         Al Amri (2016)       8.7%       0.59 (0.2)       2.3 (0.62)       62 (5.0)         6.8%       0.58 (0.15)       2.3 (0.15)       62 (7.0)         4.5%       0.46 (0.16)       1.6 (0.05)       40 (6.0)         Aguilar (2016)       NR       1.92 (1.78)       3.68 (2.25)       74 (23.45)         0.98 (1.48)       2.79 (1.31)       51 (27.39)         0.72 (1.55)       2.67 (0.80)       44 (40.21)         Erdogan (2015)       6.7%       1.13 (0.34)       NR       NR         0.93 (0.31)       0.70 (0.63)       2.40 (0.83)       72 (19.9)         Gómez-Moreno (2015)       NR       0.70 (0.63)       2.40 (0.83)       72 (19.9)         0.64 (0.56)       2.34 (0.66)       62 (19.9)       0.57 (0.78)       2.30 (1.13)       56 (34.3)         0.53 (0.78)       2.30 (1.13)       56 (34.3)       0.53 (0.78)       2.26 (0.87)       45 (27.5)         Tatarakis (2014)       7.1%       0.19 (0.45)       2.35 (0.67)       67 (22.45)         5.7%       -0.08 (0.25)       2.20 (0.89)       56 (25.46)         Bignozzi (2013)       9.05%       1.07 (0.12)       2.81 (0.31)       31 (14.0)         5.95%       0.88 (0.25)       <	Al Zahrani (2018)		8.2%	1.1	(0.81)	NR		NR
Al Amri (2016)       8.7%       0.59 (0.2)       2.3 (0.62)       62 (5.0)         6.8%       0.58 (0.15)       2.3 (0.15)       62 (7.0)         4.5%       0.46 (0.16)       1.6 (0.05)       40 (6.0)         Aguilar (2016)       NR       1.92 (1.78)       3.68 (2.25)       74 (23.45)         Aguilar (2016)       NR       1.92 (1.78)       3.68 (2.25)       74 (23.45)         Corr (1.55)       2.67 (0.80)       44 (40.21)         Erdogan (2015)       6.7%       1.13 (0.34)       NR       NR         O.72 (1.55)       2.67 (0.80)       44 (40.21)         Erdogan (2015)       NR       0.93 (0.31)       NR       0.93 (0.31)         Gómez-Moreno (2015)       NR       0.70 (0.63)       2.40 (0.83)       72 (19.9)         0.64 (0.56)       2.34 (0.66)       62 (19.9)       0.57 (0.78)       2.30 (1.13)       56 (34.3)         0.53 (0.78)       2.30 (1.13)       56 (34.3)       0.53 (0.78)       2.26 (0.87)       45 (27.5)         Tatarakis (2014)       7.1%       0.19 (0.45)       2.35 (0.67)       67 (22.45)         5.7%       -0.08 (0.25)       2.20 (0.89)       56 (25.46)         Bignozzi (2013)       9.05%       1.07 (0.12)       2.81 (0.31)			4.7%	0.58	(0.70)			
6.8%         0.58 (0.15)         2.3 (0.15)         62 (7.0)           4.5%         0.46 (0.16)         1.6 (0.05)         40 (6.0)           Aguilar (2016)         NR         1.92 (1.78)         3.68 (2.25)         74 (23.45)           0.98 (1.48)         2.79 (1.31)         51 (27.39)           0.72 (1.55)         2.67 (0.80)         44 (40.21)           Erdogan (2015)         6.7%         1.13 (0.34)         NR         NR           Gómez-Moreno (2015)         NR         0.93 (0.31)         72 (19.9)         0.64 (0.56)         2.34 (0.66)         62 (19.9)           Gómez-Moreno (2015)         NR         0.70 (0.63)         2.40 (0.83)         72 (19.9)         0.57 (0.78)         2.30 (1.13)         56 (34.3)           1         0.57 (0.78)         2.30 (1.13)         56 (34.3)         56 (34.3)         56 (34.3)           0.53 (0.78)         2.26 (0.87)         45 (27.5)         5.7%         -0.08 (0.25)         2.20 (0.89)         56 (22.45)           5.7%         -0.08 (0.25)         2.20 (0.89)         56 (24.5)         56 (24.5)         56 (24.5)           Bignozzi (2013)         9.05%         1.07 (0.12)         2.81 (0.31)         31 (14.0)	Al Amri (2016)		8.7%	0.59	(0.2)	2.3 (0.62)		62 (5.0)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$			6.8%	0.58	(0.15)	2.3 (0.15)		62 (7.0)
Aguilar (2016)         NR         1.92 (1.78)         3.68 (2.25)         74 (23.45)           0.98 (1.48)         2.79 (1.31)         51 (27.39)           0.72 (1.55)         2.67 (0.80)         44 (40.21)           Erdogan (2015)         6.7%         1.13 (0.34)         NR         NR           0.72 (1.55)         2.67 (0.80)         44 (40.21)           Gómez-Moreno (2015)         6.7%         1.13 (0.34)         NR         NR           0.64 (0.56)         2.34 (0.66)         62 (19.9)         0.57 (0.78)         2.30 (1.13)         56 (34.3)           0.53 (0.78)         2.30 (1.13)         56 (34.3)         0.53 (0.78)         2.26 (0.87)         45 (27.5)           Tatarakis (2014)         7.1%         0.19 (0.45)         2.35 (0.67)         67 (22.45)           5.7%         -0.08 (0.25)         2.20 (0.89)         56 (25.46)           Bignozzi (2013)         9.05%         1.07 (0.12)         2.81 (0.31)         31 (14.0)           5.95%         0.88 (0.25)         2.68 (0.3)         15 (23.0)			4.5%	0.46	(0.16)	1.6 (0.05)		40 (6.0)
0.98 (1.48)         2.79 (1.31)         51 (27.39)           Erdogan (2015)         6.7%         1.13 (0.34)         NR         NR           Sómez-Moreno (2015)         6.7%         1.13 (0.34)         NR         NR           Gómez-Moreno (2015)         NR         0.70 (0.63)         2.40 (0.83)         72 (19.9)           0.64 (0.56)         2.34 (0.66)         62 (19.9)         0.57 (0.78)         2.30 (1.13)         56 (34.3)           0.53 (0.78)         2.26 (0.87)         45 (27.5)         1.57%         -0.08 (0.25)         2.20 (0.89)         56 (22.45)           Bignozzi (2013)         9.05%         1.07 (0.12)         2.81 (0.31)         31 (14.0)         5.95%         0.88 (0.25)         2.68 (0.3)         15 (23.0)	Aquilar (2016)		NR	1.92	(1.78)	3.68 (2.25)		74 (23.45)
0.72 (1.55)         2.67 (0.80)         44 (40.21)           Erdogan (2015)         6.7%         1.13 (0.34)         NR         NR           NR         0.93 (0.31)         0.67%         0.664 (0.56)         2.34 (0.66)         62 (19.9)           Gómez-Moreno (2015)         NR         0.70 (0.63)         2.40 (0.83)         72 (19.9)           0.64 (0.56)         2.34 (0.66)         62 (19.9)         0.57 (0.78)         2.30 (1.13)         56 (34.3)           0.53 (0.78)         2.26 (0.87)         45 (27.5)         714         0.19 (0.45)         2.35 (0.67)         67 (22.45)           Tatarakis (2014)         7.1%         0.19 (0.45)         2.35 (0.67)         67 (22.45)           Bignozzi (2013)         9.05%         1.07 (0.12)         2.81 (0.31)         31 (14.0)           5.95%         0.88 (0.25)         2.68 (0.3)         15 (23.0)	5			0.98	(1.48)	2.79 (1.31)		51 (27.39)
Erdogan (2015)         6.7%         1.13 (0.34)         NR         NR           NR         0.93 (0.31)         0.93 (0.31)         0.67%         0.93 (0.31)         0.93 (0.31)         0.93 (0.31)         0.93 (0.31)         0.93 (0.31)         0.93 (0.31)         0.93 (0.31)         0.93 (0.31)         0.93 (0.31)         0.53 (0.66)         0.240 (0.83)         72 (19.9)         0.64 (0.56)         2.34 (0.66)         62 (19.9)         0.57 (0.78)         2.30 (1.13)         56 (34.3)         0.53 (0.78)         2.26 (0.87)         45 (27.5)         7 (22.45)         5.7%         0.19 (0.45)         2.35 (0.67)         67 (22.45)         5.7%         -0.08 (0.25)         2.20 (0.89)         56 (25.46)         56 (25.46)         5.95%         0.88 (0.25)         2.68 (0.3)         15 (23.0)				0.72	(1.55)	2.67 (0.80)		44 (40.21)
NR         0.93 (0.31)           Gómez-Moreno (2015)         NR         0.70 (0.63)         2.40 (0.83)         72 (19.9)           0.64 (0.56)         2.34 (0.66)         62 (19.9)           0.57 (0.78)         2.30 (1.13)         56 (34.3)           0.53 (0.78)         2.26 (0.87)         45 (27.5)           Tatarakis (2014)         7.1%         0.19 (0.45)         2.35 (0.67)         67 (22.45)           5.7%         -0.08 (0.25)         2.20 (0.89)         56 (25.46)           Bignozzi (2013)         9.05%         1.07 (0.12)         2.81 (0.31)         31 (14.0)	Erdogan (2015)		6.7%	1.13	(0.34)	NR		NR
Gómez-Moreno (2015)         NR         0.70 (0.63)         2.40 (0.83)         72 (19.9)           0.64 (0.56)         2.34 (0.66)         62 (19.9)           0.57 (0.78)         2.30 (1.13)         56 (34.3)           0.53 (0.78)         2.26 (0.87)         45 (27.5)           Tatarakis (2014)         7.1%         0.19 (0.45)         2.35 (0.67)         67 (22.45)           5.7%         -0.08 (0.25)         2.20 (0.89)         56 (25.46)           Bignozzi (2013)         9.05%         1.07 (0.12)         2.81 (0.31)         31 (14.0)	5	1	NR	0.93	(0.31)			
0.64 (0.56)         2.34 (0.66)         62 (19.9)           0.57 (0.78)         2.30 (1.13)         56 (34.3)           0.53 (0.78)         2.26 (0.87)         45 (27.5)           Tatarakis (2014)         7.1%         0.19 (0.45)         2.35 (0.67)         67 (22.45)           5.7%         -0.08 (0.25)         2.20 (0.89)         56 (25.46)           Bignozzi (2013)         9.05%         1.07 (0.12)         2.81 (0.31)         31 (14.0)           5.95%         0.88 (0.25)         2.68 (0.3)         15 (23.0)	Gómez-Moreno (2015)	1	NR	0.70	(0.63)	2.40 (0.83)		72 (19.9)
0.57 (0.78)         2.30 (1.13)         56 (34.3)           0.53 (0.78)         2.26 (0.87)         45 (27.5)           Tatarakis (2014)         7.1%         0.19 (0.45)         2.35 (0.67)         67 (22.45)           5.7%         -0.08 (0.25)         2.20 (0.89)         56 (25.46)           Bignozzi (2013)         9.05%         1.07 (0.12)         2.81 (0.31)         31 (14.0)           5.95%         0.88 (0.25)         2.68 (0.3)         15 (23.0)				0.64	(0.56)	2.34 (0.66)		62 (19.9)
0.53 (0.78)         2.26 (0.87)         45 (27.5)           Tatarakis (2014)         7.1%         0.19 (0.45)         2.35 (0.67)         67 (22.45)           5.7%         -0.08 (0.25)         2.20 (0.89)         56 (25.46)           Bignozzi (2013)         9.05%         1.07 (0.12)         2.81 (0.31)         31 (14.0)           5.95%         0.88 (0.25)         2.68 (0.3)         15 (23.0)				0.57	(0.78)	2.30 (1.13)		56 (34.3)
Tatarakis (2014)         7.1%         0.19 (0.45)         2.35 (0.67)         67 (22.45)           5.7%         -0.08 (0.25)         2.20 (0.89)         56 (25.46)           Bignozzi (2013)         9.05%         1.07 (0.12)         2.81 (0.31)         31 (14.0)           5.95%         0.88 (0.25)         2.68 (0.3)         15 (23.0)				0.53	(0.78)	2.26 (0.87)		45 (27.5)
5.7%         -0.08 (0.25)         2.20 (0.89)         56 (25.46)           Bignozzi (2013)         9.05%         1.07 (0.12)         2.81 (0.31)         31 (14.0)           5.95%         0.88 (0.25)         2.68 (0.3)         15 (23.0)	Tatarakis (2014)		7.1%	0.19	(0.45)	2.35 (0.67)		67 (22.45)
Bignozzi (2013)         9.05%         1.07 (0.12)         2.81 (0.31)         31 (14.0)           5.95%         0.88 (0.25)         2.68 (0.3)         15 (23.0)	. ,		5.7%	-0.08	(0.25)	2.20 (0.89)		56 (25.46)
5.95%         0.88 (0.25)         2.68 (0.3)         15 (23.0)	Bignozzi (2013)		9.05%	1.07	(0.12)	2.81 (0.31)		31 (14.0)
			5.95%	0.88	(0.25)	2.68 (0.3)		15 (23.0)

#### Table 2. Characteristics of included studies.

RA: retrospective analysis; PA: prospective analysis; NA: not applicable; y: year; m: month; NR: not reported.

bone loss values of the diabetes group were significantly higher than that of the control group; five other studies [18,19,26,27,29] reported higher marginal bone loss in diabetes patients, than that in patients without diabetes, but the difference was not statistically significant. In regard to PD, probing depth of patients without diabetes was significantly lower than that of patients with diabetes. Six studies [18,19,24,25,27,29] reported higher PD among patients with diabetes than those without, but the difference was not statistically significant. Due to high heterogeneity between studies, we conducted a subgroup analysis and found that loading time – but not HbA1c levels – may be the source of heterogeneity. With delayed loading, there was no statistically significant difference in PD between patients with and without diabetes (p = .15); however, the PD of diabetes patients with immediate loading implants was significantly higher. In terms of BOP, the review results showed worse BOP in patients with diabetes mellitus versus those without. In four studies [18,20,25,27], the BOP of participants with diabetes was significantly higher than that of the participants without diabetes; in the remaining two studies [24,29], the differences in BOP between the two groups were not statistically significant. To determine the source of this high heterogeneity, we performed a subgroup analysis, which indicated that both loading time and HbA1c could be sources of heterogeneity. As HbA1c levels increase, BOP of the surrounding tissues of the implant will also increase. This result could occur because increased HbA1c levels inhibit oxygen-carrying capacity and reduce the resistance of tissues [38]. In terms of loading time, subgroup analysis results suggested that the heterogeneity could have been caused by a third 'other' group. In fact, neither Al-Sowygh [20] nor Tatarakis [28] distinguished between various dental implant loading times; their papers were therefore categorized into a separate group, considering that the study participants could include patients with both immediate and delayed loading. However, the hypothesis that loading time may be the source of high heterogeneity should be considered with caution.

In a meta-analysis, Moraschini et al. [39] compared the implant success rate and marginal bone loss of diabetes patients with that of healthy patients and found no statistically significant difference between the two groups in terms of implant success rate; however, the marginal bone loss of the diabetes group was significantly higher than that of the healthy group. In another meta-analysis, Alberto et al. [40] found a significantly higher risk of peri-implantitis in diabetes patients than in healthy participants, but the risk of peri-implant mucositis was not significantly different between the two groups. However, there are no globally accepted definitions of peri-implant disease [41], rendering the homogeneity

 Table 3. Quality assessment of 10 studies included in the qualitative evaluation according to the New Castle Ottawa Scale (NOS)

Author (Year)	Study design	Selection (Max 4)	Comparability (Max 2)	Outcome (Max 3)
Abdulaziz (2019)	RC	**	**	**
Cabrera-Dominguez (2019)	PC	***	**	***
Al-Sowygh [20]	RC	**	*	*
Al Zahrani [21]	PC	***	**	***
Al Amri [24]	PC	**	*	**
Aguilar-Salvatierra [25]	PC	*	**	***
Erdogan [26]	PC	***	*	**
Gomez-Moreno (2015)	PC	***	*	**
Tatarakis [28]	PC	***	*	**
Bignozzi [29]	PC	****	*	***

A maximum of one star for each item within the selection categories: representativeness of the exposed cohort, selection of external control, ascertainment of exposure, outcome of interest not present at start.

A maximum of one star for each item within the outcome categories: assessment of outcome, follow-up was long enough for outcome to occur, adequacy of follow-up of cohorts.

A study can be awarded maximum two stars in the comparability.

of the included studies potentially low, and direct comparison should be conducted with caution. The successful implant criteria proposed by Albrektsson et al. [42] in 1986 have been widely recognized, mainly including: no mobility of the implant, no evidence of radiolucency around the implant, bone loss in the vertical direction is less than 0.2 mm per year following the implant's first year of service, For non-persistent or irreversible complications after implantation, the above conditions were satisfied for more than 85% in 5 years and 80% in 10 years. The clinical assessment level proposed by the International Congress of Oral Implantologists Consensus Conference in 2007[43] was widely recognized and defined implant success as: No pain or tenderness upon function, 0 mobility, <2 mm radiographic bone loss from initial surgery, No exudates history. periimplantitis refers to the pathological state of the peri-implant tissues caused by plaque, characterized by the appearance of mucosal inflammation around the implant and the gradual absorption of the supporting bone tissues. It is a major reason of implant failure, accompanied with bleeding, increased probing depth, and marginal bone loss [44,45].

Whether immediate loading affects the survival rate and long-term consequences of dental implants has remained controversial. Al Amri et al. [24] and Aguilar et al. [25] reported that immediate loading and delayed loading had no significant effect on the severity of peri-implant complications in patients with well-controlled diabetes mellitus. In contrast, Michaeli et al. [4,42] supported the hypothesis that the implant for diabetes patients should not be immediately loaded, as it may lead to impaired healing of the bone around the implant; however, this may be because HbA1c were not well controlled in that study. Thus, regarding immediate implantation and implant loading for patients with diabetes mellitus, it is suggested that doctors carefully consider indications and ensure that HbA1c is well-controlled.

HbA1c is the main manifestation of stable glycosylated haemoglobin, which is essentially an irreversible product of the red blood cell cycle. HbA1c reflects changes in the blood glucose level over the preceding 2–3 months and can be modified into advanced glycosylation products (AGEs); these can inhibit the development of osteoblasts and promote the inflammatory response of periodontal tissues [43–48]. HbA1c



Figure 2. Forest plot of the random effects model meta-analysis of studies reporting MBL.

(a)	di	abetes	5	non-	-diabe	tes		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.2.1 delayed loading									
Abdulaziz(5.7%-6.4%) 2019	2.23	1.85	78	2.18	1.3	52	7.4%	0.05 [-0.49, 0.59]	
Abdulaziz(≧6.5%) 2019	2.39	1.45	65	2.18	1.3	52	8.0%	0.21 [-0.29, 0.71]	
Bignozzi 2013	2.81	0.31	8	2.68	0.3	22	11.7%	0.13 [-0.12, 0.38]	
Cabrera-Domînguez 2019	2.13	0.68	14	2.07	0.78	14	7.4%	0.06 [-0.48, 0.60]	
Gómez-Moreno(6.1%-8%) 2015	2.3	1.13	24	2.26	0.87	21	6.9%	0.04 [-0.55, 0.63]	
Gómez-Moreno(8.1-10%) 2015	2.34	0.66	11	2.26	0.87	21	7.5%	0.08 [-0.46, 0.62]	
Gómez-Moreno(≧10%) 2015	2.4	0.83	11	2.26	0.87	21	6.6%	0.14 [-0.48, 0.76]	
Tatarakis 2014	2.35	0.67	14	2.2	0.89	18	7.5%	0.15 [-0.39, 0.69]	
Subtotal (95% CI)			225			221	63.0%	0.12 [-0.04, 0.28]	◆
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup>	= 0.35,	df = 1	7 (P = 1	1.00); I <sup>2</sup>	= 0%				
Test for overall effect: $Z = 1.43$ (	P = 0.15	5)							
1.2.2 immediate loading									
Aguilar(6.1%-8%) 2016	2.79	1.31	30	2.67	0.8	33	7.4%	0.12 [-0.42, 0.66]	
Aguilar(8.1%-10%) 2016	3.68	2.25	22	2.67	0.8	33	3.6%	1.01 [0.03, 1.99]	
Al Amri(6.1%-8%) 2016	2.3	0.15	30	1.6	0.05	30	13.7%	0.70 [0.64, 0.76]	-
Al Amri(8.1%-10%) 2016	2.3	0.62	31	1.6	0.05	30	12.2%	0.70 [0.48, 0.92]	
Subtotal (95% CI)			113			126	37.0%	0.66 [0.51, 0.82]	•
Heterogeneity: $Tau^2 = 0.01$ ; Chi <sup>2</sup>	= 4.75,	df = 1	3 (P = 0)	).19); I <sup>2</sup>	= 37%	6			
Test for overall effect: Z = 8.32 (	P < 0.00	0001)							
Total (95% CI)			338			347	100.0%	0.30 [0.08, 0.51]	◆
Heterogeneity: $Tau^2 = 0.09$ ; Chi <sup>2</sup>	= 50.42	7. df =	11 (P	< 0.000	001): I <sup>2</sup>	= 78%			
Test for overall effect: $Z = 2.68$ (	P = 0.00	)7)			// -				-2 -1 0 1 2
Test for subgroup differences: C	$hi^2 = 23$	13 df	= 1 (P)	< 0.00	001)	$ ^2 - 95$	7%		diabetes non-diabetes



Figure 3. Forest plot of the random effects model meta-analysis of the effect of diabetes mellitus on the probing depth of dental implants, and subgroup analysis based on loading time (a) and HbA1c levels (b).

is considered the diagnostic standard for diabetes mellitus, and controlling HbA1c levels is the main method for controlling and monitoring diabetes [4,46,49,50]. Three studies [24,25,27] were grouped according to different control levels of HbA1c and analysed for variables related to tissue response around implants, which was found to be related to HbA1c levels and time.

Our findings seem to suggest that MBL, PD and BOP around dental implants are higher in individuals with diabetes mellitus. However, some issues should be considered.

First, the control level of diabetes was evaluated by measuring HbA1c. However, most of the ten papers included in this review only provided initial data of HbA1c. Although three articles [22,25,27] mentioned this indicator for monitoring diabetes, these papers did not provide the relevant data or analysis. One article [24] described a reduction in patients' HbA1c levels by means of periodontal maintenance and that peri-implant inflammation indicators were then improved. Another study [28] mentioned that HbA1c levels in patients with diabetes were maintained at initial levels and that they remained stable throughout the follow-up period. Second, the search strategy we adopted did not retrieve relevant RCTs, and mainly retrieved cohort studies. Compared with RCTs, nonrandomized controlled methods are more likely to

(a)	diabetes non-diabetes					es		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.3.1 delayed loading									
Abdulaziz(5.7%-6.4%) 2019	42	70.7	78	21	43.4	52	5.6%	21.00 [1.37, 40.63]	
Abdulaziz(≥6.5%) 2019	53	56.4	65	21	43.4	52	6.2%	32.00 [13.91, 50.09]	
Bignozzi 2013	31	14	8	15	23	22	8.3%	16.00 [2.34, 29.66]	
Gómez-Moreno(6.1%-8%) 2015	56	34.3	24	45	27.5	21	6.2%	11.00 [-7.07, 29.07]	
Gómez-Moreno(8.1-10%) 2015	62	19.9	11	45	27.5	21	6.8%	17.00 [0.37, 33.63]	
Gómez–Moreno(≥10%) 2015	72	19.9	11	45	27.5	21	6.8%	27.00 [10.37, 43.63]	
Subtotal (95% CI)			197			189	40.0%	20.22 [13.37, 27.07]	•
Heterogeneity: $Tau^2 = 0.00$ ; $Chi^2$	= 3.78,	df = 5	(P = 0.	58); I <sup>2</sup> =	= 0%				
Test for overall effect: $Z = 5.79$ (F	<b>'</b> < 0.00	001)							
1.3.2 immediate loading									
Aquilar(6, 1%-8%) 2016	51	27.39	13	44	40.21	18	4.3%	7.00 [-16.81, 30.81]	
Aquilar(8,1%-10%) 2016	74	23.45	13	44	40.21	18	4.6%	30 00 [7 47 52 53]	
Al Amri(6.1%–8%) 2016	62	23.13	30	40	6	30	14.8%	22 00 [18 70 25 30]	-
Al Amri(8,1%-10%) 2016	62	5	31	40	6	30	15.0%	22.00 [19.22, 24.78]	-
Subtotal (95% CI)	02	5	87	10	0	96	38.7%	21.95 [19.85, 24.06]	•
Heterogeneity: $Tau^2 = 0.00$ : $Chi^2$	= 2.01.	df = 3	(P = 0.	57): 1 <sup>2</sup> =	= 0%				
Test for overall effect: $Z = 20.43$	(P < 0.0	00001)							
1.3.3 other									
Al-Sowygh 2018	62.3	7.9	39	24.7	9.5	40	14.5%	37.60 [33.75, 41.45]	
Tatarakis 2014	67	22.4	14	56	25.46	18	6.8%	11.00 [-5.61, 27.61]	
Subtotal (95% CI)			53			58	21.3%	25.58 [-0.37, 51.52]	
Heterogeneity: Tau <sup>2</sup> = 315.93; Ch	$1i^2 = 9.3$	35, df =	1 (P =	0.002)	$1^2 = 89$	9%			
Test for overall effect: $Z = 1.93$ (F	<b>?</b> = 0.05	5)							
Total (95% CI)			337			343	100.0%	22.62 [16.82, 28.43]	•
Heterogeneity: $Tau^2 = 56.57$ : Chi	$^{2} = 59.5$	59. df =	11 (P ·	< 0.000	01); I <sup>2</sup>	= 82%			
Test for overall effect: $Z = 7.64$ (F	2 < 0.00	001)			_,, :				-50 -25 0 25 50
Test for subgroup differences: Ch	$1i^2 = 0.3$	0. df =	2(P =	0.86) 1	$^{2} = 0\%$				diabetes non-diabetes

	d	iabetes		non	-diabet	es		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.3.1 6.1%-8.0%									
Abdulaziz(5.7%–6.4%) 2019	42	70.7	78	21	43.4	52	5.6%	21.00 [1.37, 40.63]	
Abdulaziz(≧6.5%) 2019	53	56.4	65	21	43.4	52	6.2%	32.00 [13.91, 50.09]	
Aguilar(6.1%–8%) 2016	51	27.39	13	44	40.21	18	4.3%	7.00 [-16.81, 30.81]	
A Amri(6.1%–8%) 2016	62	7	30	40	6	30	14.8%	22.00 [18.70, 25.30]	+
ómez–Moreno(6.1%–8%) 2015	56	34.3	24	45	27.5	21	6.2%	11.00 [-7.07, 29.07]	
atarakis 2014	67	22.4	14	56	25.46	18	6.8%	11.00 [-5.61, 27.61]	
ubtotal (95% CI)			224			191	43.9%	20.38 [15.48, 25.28]	•
leterogeneity: Tau <sup>2</sup> = 6.31; Chi <sup>2</sup>	= 5.63,	df = 5	(P = 0.1)	34); I <sup>2</sup> =	= 11%				
Test for overall effect: $Z = 8.15$ (	P < 0.00	001)							
.3.2 8.1%-10.0%									
.guilar(8.1%–10%) 2016	74	23.45	13	44	40.21	18	4.6%	30.00 [7.47, 52.53]	
l Amri(8.1%-10%) 2016	62	5	31	40	6	30	15.0%	22.00 [19.22, 24.78]	-
ignozzi 2013	31	14	8	15	23	22	8.3%	16.00 [2.34, 29.66]	
Gómez-Moreno(8.1–10%) 2015	62	19.9	11	45	27.5	21	6.8%	17.00 [0.37, 33.63]	
ubtotal (95% CI)			63			91	34.8%	21.75 [19.09, 24.42]	•
leterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup>	= 1.54,	df = 3	(P = 0.0)	67); I <sup>2</sup> =	= 0%				
est for overall effect: $Z = 15.99$	(P < 0.0	0001)							
3.3 ≧10.0%									
I-Sowygh 2018	62.3	7.9	39	24.7	9.5	40	14.5%	37.60 [33.75, 41.45]	
lómez–Moreno(≥10%) 2015	72	19.9	11	45	27.5	21	6.8%	27.00 [10.37, 43.63]	
ubtotal (95% CI)			50			61	21.3%	35.51 [27.26, 43.77]	•
leterogeneity: Tau <sup>2</sup> = 18.25; Chi	$i^2 = 1.48$	3, df =	1 (P = 0)	).22); I <sup>2</sup>	= 32%				
Test for overall effect: $Z = 8.43$ (	P < 0.00	0001)							
otal (95% CI)			337			343	100.0%	22.62 [16.82, 28.43]	•
leterogeneity: $Tau^2 = 56.57$ : Chi	$i^2 = 59.5$	59. df =	11 (P -	< 0.000	01): I <sup>2</sup>	= 82%			
est for overall effect: $7 = 7.64$ (	P < 0.00	0001)	(.		/, •	22/0			-50 -25 0 25
est for subgroup differences: Ch	$hi^2 - 10$	56 df	- 2 (P -	- 0 005	$1^2 - 8$	1 1%			diabetes non-diabetes

Figure 4. Forest plot of the random effects model meta-analysis for the comparison between diabetic group and control group regarding bleeding on probing. 'forest plot' of subgroup based on loading time (a) and HbA1c levels (b).

generate potential bias. Finally, although the results were statistically significant, the small number of studies and participants results in lower statistical power.

In conclusion, despite the limitations of this review, implants are feasible for patients with diabetes. There is evidence, however, that these patients are more likely to have clinical complications than patients without diabetes. For primary outcome (marginal bone loss), there was a statistically significant difference favouring non-diabetic subjects. Additionally, for secondary outcomes, the comparison of different HbA1c levels showed no evidence of a higher PD for all of the groups. However, the differences of BOP around implants were significant of all the three HbA1c levels, favouring systemically healthy individuals. This evidence suggests that dental implant eligibility criteria for patients with diabetes should be more strict, that local and systemic factors should be controlled for after surgery, and that longterm follow-up and evaluations should performed.

## Acknowledgments

The authors thank Natural Science Foundation of China for their financial support.

#### **Disclosure statement**

No potential conflict of interest was reported by the author(s).

## Funding

This work was supported by the Natural Science Foundation of China [grant numbers 81671033] and Graduate Innovation Fund of Jilin University [grant number 101832018C081].

#### ORCID

Song Zhu (i) http://orcid.org/0000-0001-6935-9490

#### References

- Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018; 138:271–281.
- [2] Bacić M, Plancak D, Granić M. CPITN assessment of periodontal disease in diabetic patients. J Periodontol. 1988;59:816–822.
- [3] Shurtz-Swirski R, Sela S, Herskovits AT, et al. Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetic patients. Diabetes Care. 2001;24: 104–110.
- [4] Michaeli E, Weinberg I, Nahlieli O. Dental implants in the diabetic patient: systemic and rehabilitative considerations. Quintessence Int. 2009;40:639–645.
- [5] Jung HY, Kim YG, Jin MU, et al. Relationship of tooth mortality and implant treatment in Type 2 diabetes mellitus patients in Korean adults. J Adv Prosthodont. 2013;5:51–57.
- [6] Luo H, Pan W, Sloan F, et al. Forty-year trends in tooth loss among american adults with and without diabetes mellitus: an age-period-cohort analysis. Prev Chronic Dis. 2015;12:E211.
- [7] King S, Klineberg I, Levinger I, et al. The effect of hyperglycaemia on osseointegration:a review of animal models of diabetes mellitus and titanium implant placement. Arch Osteoporos. 2016;11: 29.
- [8] Venza I, Visalli M, Cucinotta M, et al. Proinflammatory gene expression at chronic periodontitis and peri-implantitis sites in patients with or without type 2 diabetes. J Periodontol. 2010; 81: 99–108.
- [9] Salvi GE, Lang NP. Diagnostic parameters for monitoring periimplant conditions. Int J Oral Maxillofac Implants. 2004;19 Suppl: 116–127.
- [10] Lang NP, Berglundh T; on Behalf of Working Group 4 of the Seventh European Workshop on Periodontology. Periimplant diseases: where are we now? – consensus of the Seventh European Workshop on Periodontology. J Clin Periodontol. 2011;38: 178–181.
- [11] Albrektsson T, Donos N; Working Group 1. Implant survival and complications. The Third EAO consensus conference 2012. Clin Oral Implants Res. 2012;23:63–65.

- [12] Figuero E, Graziani F, Sanz I, et al. Management of peri-implant mucositis and peri-implantitis. Periodontol 2000. 2014;66: 255–273.
- [13] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015statement. Rev Esp Nutr Hum Diet. 2016; 20:148–160.
- [14] Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical\_epidemiology/oxford.asp
- [15] Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions (version 5.1). Available from: http://www. cochrane.org/handbook
- [16] Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
- [17] Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
- [18] Alsahhaf A, Alshiddi IF, Alshagroud RS, et al. Clinical and radiographic indices around narrow diameter implants placed in different glycemic-level patients. Clin Implant Dent Relat Res. 2019;21: 621–626.
- [19] Cabrera-Domínguez JJ, Castellanos-Cosano L, Torres-Lagares D, et al. Clinical performance of titanium-zirconium implants with a hydrophilic surface in patients with controlled type 2 diabetes mellitus: 2-year results from a prospective case-control clinical study. Clin Oral Investig. 2019.
- [20] Al-Sowygh ZH, Al-Kheraif AA, Akram Z, et al. Peri-implant soft tissue inflammatory parameters and crestal bone loss among waterpipe (narghile) smokers and never-smokers with and without type 2 diabetes mellitus. J Periodontol. 2018; 89:645–652.
- [21] Al Zahrani S, Al Mutairi AA. Stability and bone loss around submerged and non-submerged implants in diabetic and non-diabetic patients: a 7-year follow-up. Braz Oral Res. 2018;32:e57.
- [22] Cabrera-Domínguez J, Castellanos-Cosano L, Torres-Lagares D, et al. A prospective case-control clinical study of titanium-zirconium alloy implants with a hydrophilic surface in patients with type 2 diabetes mellitus. Int J Oral Maxillofac Implants. 2017;32: 1135–1144.
- [23] Abduljabbar T, Al-Sahaly F, Al-Kathami M, et al. Comparison of periodontal and peri-implant inflammatory parameters among patients with prediabetes, type 2 diabetes mellitus and non-diabetic controls. Acta Odontol Scand. 2017;75:319–324.
- [24] Al Amri MD, Kellesarian SV, Al-Kheraif AA, et al. Effect of oral hygiene maintenance on HbA1c levels and peri-implant parameters around immediately-loaded dental implants placed in type-2 diabetic patients: 2 years follow-up. Clin Oral Impl Res. 2016;27: 1439–1443.
- [25] Aguilar-Salvatierra A, Calvo-Guirado JL, González-Jaranay M, et al. Peri-implant evaluation of immediately loaded implants placed in esthetic zone in patients with diabetes mellitus type 2: a twoyear study. Clin Oral Impl Res. 2016;27:156–161.
- [26] Erdogan Ö, Uçar Y, Tatlı U, et al. A clinical prospective study on alveolar bone augmentation and dental implant success in patients with type 2 diabetes. Clin Oral Impl Res. 2015;26: 1267–1275.
- [27] Gómez-Moreno G, Aguilar-Salvatierra A, Rubio Roldán J, et al. Peri-implant evaluation in type 2 diabetes mellitus patients: a 3year study. Clin Oral Impl Res. 2015;26:1031–1035.
- [28] Tatarakis N, Kinney JS, Inglehart M, et al. Clinical, microbiological, and salivary biomarker profiles of dental implant patients with type 2 diabetes. Clin Oral Impl Res. 2014;25:803–812.
- [29] Bignozzi I, Ciobanu G, Quaranta A, et al. Dental implant sites in healthy versus diabetic subjects: a two-year clinical and bacteriological assessment. Eur J Inflamm. 2013;11:813–823.
- [30] Mokeem S, Alfadda SA, Al-Shibani N, et al. Clinical and radiographic peri-implant variables around short dental implants in type 2 diabetic, prediabetic, and non-diabetic patients. Clin Implant Dent Relat Res. 2019;21:60–65.
- [31] Alrabiah M, Al-Aali KA, Al-Sowygh ZH, et al. Association of advanced glycation end products with peri-implant inflammation

in prediabetes and type 2 diabetes mellitus patients. Clin Implant Dent Relat Res. 2018;20:535–540.

- [32] Al Amri MD, Abduljabbar TS, Al-Kheraif AA, et al. Comparison of clinical and radiographic status around dental implants placed in patients with and without prediabetes: 1-year follow-up outcomes. Clin Oral Impl Res. 2017;28:231–235.
- [33] Al-Sowygh ZH, Ghani SMA, Sergis K, et al. Peri-implant conditions and levels of advanced glycation end products among patients with different glycemic control. Clin Implant Dent Relat Res. 2018;20:345–351.
- [34] Al Zahrani S, Al Mutairi AA. Crestal bone loss around submerged and non-submerged dental implants in individuals with type-2 diabetes mellitus: a 7-year prospective clinical study. Med Princ Pract. 2019;28:75–81.
- [35] Al-Shibani N, Al-Aali KA, Al-Hamdan RS, et al. Comparison of clinical peri-implant indices and crestal bone levels around narrow and regular diameter implants placed in diabetic and non-diabetic patients: a 3-year follow-up study. Clin Implant Dent Relat Res. 2019;21:247–252.
- [36] Alasqah MN, Alrabiah M, Al-Aali KA, et al. Peri-implant soft tissue status and crestal bone levels around adjacent implants placed in patients with and without type-2 diabetes mellitus: 6 years follow-up results. Clin Implant Dent Relat Res. 2018;20:562–568.
- [37] Alrabiah M, Alrahlah A, Al-Hamdan RS, et al. Survival of adjacentdental-implants in prediabetic and systemically healthy subjects at 5-years follow-up. Clin Implant Dent Relat Res. 2019;21: 232–237.
- [38] Garg S, Gupta S, Mobeen MS, et al. Effect of obesity and glycated hemoglobin on oxygen saturation in ambulatory type2 diabetic individuals: a pilot study. Diabetes Metab Syndr. 2016;10: 157–160.
- [39] Moraschini V, Barboza ESP, Peixoto GA. The impact of diabetes on dental implant failure: a systematic review and meta-analysis. Int J Oral Maxillofac Surg. 2016; 45:1237–1245.

- [40] Monje A, Catena A, Borgnakke WS. Association between diabetes mellitus/hyperglycaemia and peri-implant diseases:Systematic review and meta-analysis. J Clin Periodontol. 2017;44:636–648.
- [41] Sanz M, Chapple IL; on behalf of Working Group 4 of the VIII European Workshop on Periodontology. Clinical research on periimplant diseases: consensus report of Working Group 4. J Clin Periodontol. 2012;39:202–206.
- [42] Clin Albrektsson T, Zarb G, Worthington P, et al. The long-term efficacy of currently used dental implants: a review and proposed criteria of success. Int J Oral Maxillofac Implants. 1986;1: 11–25.
- [43] Misch CE, Perel ML, Wang HL, et al. Implant success, survival, and failure: the international congress of oral implantologists (ICOI) pisa consensus conference. Implant Dent. 2008; 17:5–15.
- [44] Lindhe J, Meyle J; on behalf of Group D of the European Workshop on Periodontology. Peri-implant diseases: consensus report of the Sixth European Workshop on Periodontology. J Clin Periodontol. 2008;35:282–285.
- [45] Arciola CR, Campoccia D, Montanaro L. Implant infections: adhesion, biofilm formation and immune evasion. Nat Rev Microbiol. 2018; 16:397–409.
- [46] Hussein RM. Biochemical relationships between bone turnover markers and blood glucose in patients with type 2 diabetes mellitus. Diabetes Metab Syndr. 2017;11 :S369–S372.
- [47] Takeda M, Ojima M, Yoshioka H, et al. Relationship of serum advanced glycation end products with deterioration of periodontitis in type 2 diabetes patients. J Periodontol. 2006;77:15–20.
- [48] Yamagishi Sl. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets. 2011;12:2096–2102.
- [49] Koenig RJ, Peterson CM, Jones RL, et al. Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. N Engl J Med. 1976;295:417–420.
- [50] American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26: S33–S50.